

Subject Index

A

ABVD (adriamycin, bleomycin, vinblastine, and DTIC), treatment of MOPP failures with Hodgkin's disease: a re-examination of goals of salvage therapy, 363

ACNU [1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea, hydrochloride], effect of, on primary lung cancer, mesothelioma, and metastatic pulmonary tumors, 139

Actinomycin analogs, comparative antitumor activity of, in mice bearing Ridgway osteogenic sarcoma or P388 leukemia, 779

Actinomycin D

with bleomycin and vincristine, compared with vinblastine and bleomycin in the treatment of disseminated germinal tumors of the testis, 129

and DTIC, phase I-II study of intermittent bolus administration of, in metastatic malignant melanoma, 1223

and DTIC with or without bacillus Calmette-Guérin in the treatment of disseminated malignant melanoma, 1085

effect of, and neoparsphenamine on tumor control and skin tolerance in the rat, 713

protective effect of hyperthermia against the cytotoxicity of, on Chinese hamster cells, 1489

relationship between plasma levels of chorionic gonadotropin and tumor growth during chemotherapy with, in human choriocarcinoma maintained in the hamster cheek pouch, 2101

in the treatment of childhood acute lymphocytic leukemia, 829

Activated macrophages, potential mechanism of macrophage-mediated tumor cell cytotoxicity, 1823

38 Adenocarcinoma *see* Tumor systems in animals

ADJ-PC5 plasmacytoma *see* Tumor systems in animals

Adriamycin

activity of, in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (Cooper's regimen), 449

adjuvant treatment with, in primary operable osteosarcoma, 279

for advanced ovarian carcinoma recurrent after chemotherapy, 1375

age-related cardiotoxicity in children treated with, 1381

alone and in various combinations, in the treatment of osteosarcoma, 237

alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide, comparison of the therapeutic effects in the treatment of cervical cancer, 1435

alopecia caused by, and the scalp tourniquet as a treatment for alopecia, 489

alteration of binding of the supravital dye Hoechst 33342 to human leukemic cells by, 1393

amphotericin B and an adriamycin-containing combination chemotherapy regimen in the treatment of refractory metastatic breast carcinoma and sarcoma, 1565

and amputation in the treatment of primary osteosarcoma: 5-year report, 271

biology and therapeutic response of mouse mammary 16/C adenocarcinoma and its potential as a model for surgical adjuvant chemotherapy, 1471

and bleomycin, phase II study in patients with multiple myeloma, 1367

cardiac dysrhythmias induced by, in an experimental dog model, 963

cardiac toxicity: early detection by systolic time interval and possible prevention by coenzyme Q₁₀, 887

cardiomyopathy monitored by morphologic changes, 865

cardiomyopathy, noninvasive profile in the prospective monitoring of, 881

cardiotoxic effects in man, invasive and noninvasive methods of assessing: superiority of histopathologic assessment using endomyocardial biopsy, 857

cardiotoxicity induced by, systolic time intervals used in monitoring, 893

and chlorambucil versus adriamycin and thiabendazole in the treatment of extensive non-small cell carcinoma of the lung, 1215

combined with bleomycin, vinblastine, and DTIC and used to treat MOPP failures with Hodgkin's disease: a re-examination of goals of salvage therapy, 363

combined with *cis*-dichlorodiammineplatinum(II) and ftorafur in the treatment of adenocarcinoma and large cell anaplastic carcinoma of the lung, 1089

combined with cyclophosphamide and *cis*-dichlorodiammineplatinum(II) in the treatment of ovarian cancer after failure of initial chemotherapy, 1021

combined with cyclophosphamide, methotrexate, and procarbazine (CAMP) in the treatment of non-oat cell bronchogenic carcinoma, 1595

combined with cyclophosphamide, methotrexate, procarbazine, and radiation therapy in the treatment of stage III_{M0} non-oat cell lung cancer, 327

combined with DTIC, in the treatment of benign and locally aggressive tumors, 167

combined with 5-fluorouracil, methyl-CCNU, and mitomycin C in the treatment of advanced stomach cancer, 1287

combined with 5-fluorouracil, mitomycin C, and cytosine arabinoside in the treatment of colorectal cancer, 1557

- combined with isophosphamide and *Corynebacterium parvum* in the treatment of extensive non-oat cell lung cancer, 1059
- combined with methotrexate in the treatment of cervical carcinoma, 1387
- combined with methotrexate, vincristine, and cyclophosphamide (MOCA) with or without bacillus Calmette-Guérin or *Corynebacterium parvum* in the treatment of unresectable lung cancer, 681
- compared with cyclophosphamide in the treatment of advanced endometrial cancer, 159
- comparison of nucleolar segregation in skeletal muscle, cardiac muscle, and liver cells induced by, 771
- and continuous-infusion 5-azacytidine in the treatment of malignant mesothelioma, 1108
- cis*-dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus *cis*-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for lung cancer, 1207
- and *cis*-dichlorodiammineplatinum(II), phase II trial in the treatment of squamous cell, ovarian, and testicular carcinomas, 1211
- and *cis*-dichlorodiammineplatinum(II), sequential responses in metastatic cloacogenic carcinoma of the anus, 91
- plus *cis*-dichlorodiammineplatinum(II) in the treatment of advanced ovarian carcinoma, 2027
- and *cis*-dichlorodiammineplatinum(II) in the treatment of testicular cancer refractory to vinblastine and bleomycin, 1351
- distribution and antitumor activity of, given in a high-dose and a repeated low-dose schedule to mice, 791
- effect of α -tocopherol on the cardiotoxicity of, in the rat, 1033
- with high-dose methotrexate and high-dose cyclophosphamide in the treatment of osteosarcoma, 247
- and high-dose methotrexate, citrovorum factor rescue, vincristine, and cyclophosphamide in the treatment of osteosarcoma, 283
- and hydroxyurea, vinblastine, and medroxyprogesterone acetate, chemohormonal therapy for metastatic renal cell carcinoma, 1379
- hypertensive reaction to, 1269
- and mitomycin C: possible synergistic cardiotoxicity, 1005
- noninvasive assessment of cardiac dysfunction in the cancer patient, 949
- noninvasive cardiac evaluation of patients receiving, 915
- overview of cardiac pathology in relation to anthracycline cardiotoxicity, 955
- as part of the multidrug adjuvant chemotherapy (CONPADRI-I, CONPADRI-II, and CONPADRI-III) for osteosarcoma, 265
- phase I clinical study of quelamycin, a synthetic triferic derivative of, 1527
- plus cyclophosphamide, *cis*-dichlorodiammineplatinum(II), vincristine, and bacillus Calmette-Guérin or *Corynebacterium parvum* in the treatment of stage III lung cancer, 505
- plus cyclophosphamide, high-dose methotrexate, and citrovorum factor in the treatment of osteosarcoma, 251
- plus cyclophosphamide in the treatment of squamous cell carcinoma of the cervix, 143
- plus 5-fluorouracil and mitomycin C, phase II trial in advanced colorectal cancer, 563
- plus high-dose methotrexate and vincristine versus transfer factor in the treatment of nonmetastatic osteosarcoma, 289
- as postoperative therapy for osteosarcoma, alternated with high-dose methotrexate and citrovorum factor rescue, 213
- prediction of disposition of, in cancer patients using a physiologic pharmacokinetic model, 1161
- prolonged complete response in malignant fibrous histiocytoma treated with, 1405
- QRS voltage change with, 931
- serial studies of cardiac function in patients receiving, 923
- subclinical cardiotoxicity: detection by timing the arterial sounds, 901
- subline of P388 leukemia resistant to, in vivo characteristics of resistance and cross-resistance of, 1535
- systolic time intervals: an effective measure of cardiac function in adriamycin-induced cardiomyopathy of rabbits, 911
- systolic time intervals in monitoring for cardiomyopathy in children receiving, 907
- time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after therapy with, 945
- and *N*-trifluoroacetyladiamycin-14-valerate, comparative antineoplastic activity of, in mice, 111
- used with methotrexate, citrovorum factor rescue, and vincristine as preoperative therapy for osteosarcoma, 217
- used with *Corynebacterium parvum*, isophosphamide, and iv hyperalimentation for squamous cell lung cancer, 1139
- and vincristine and cyclophosphamide, unusual neuromuscular toxicity after treatment of bone sarcomas, 1408
- and whole-lung radiation in the treatment of osteosarcoma, 297
- Adriamycin-DNA complex**, cardiac toxicity of, and rubidazole: evaluation by electrocardiogram and endomyocardial biopsy, 935
- AD 32** see *N*-Trifluoroacetyladiamycin-14-valerate
- Adverse effects in animals**, adriamycin-induced cardiac dysrhythmias in an experimental dog model, 963
- Adverse effects in man**
- acute cyclophosphamide hypersensitivity: possible lack of cross-sensitivity to mechlorethamine and isophosphamide, 180
- acute leukemia after prolonged immunosuppressive therapy for glomerulonephritis, 1110
- acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer, 1135
- acute myelomonocytic leukemia following a chemother-

apeutic regimen (cyclophosphamide, vincristine, adriamycin, and DTIC) for metastatic sarcoma, 1513

acute renal failure after *cis*-dichlorodiammineplatinum(II) and gentamicin-cephalothin therapies, 693

adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy, 857

adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q₁₀, 887

adriamycin and mitomycin C: possible synergistic cardiotoxicity, 1005

adverse reactions to levamisole, 1721

age-related adriamycin cardiotoxicity in children, 1381

alopecia caused by adriamycin and the scalp tourniquet as a treatment for, 489

anthracycline cardiomyopathy monitored by morphologic changes, 865

athetosis and ataxia: side effects of chemotherapy with vincristine in non-Hodgkin's lymphoma, 561

cardiac toxicity of adriamycin-DNA complex and rubidazole: evaluation by electrocardiogram and endomyocardial biopsy, 935

clinical spectrum of anthracycline antibiotic cardiotoxicity, 873

development of Hodgkin's disease in a patient being treated with vincristine, CCNU, and procarbazine for gemistocytic astrocytoma, 177

empiric antibiotic therapy for granulocytopenic cancer patients, 673

gynecomastia, with nitrosourea therapy, 574

hypertensive reaction to adriamycin, 1269

interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy, 1355

levamisole granulocytopenia in patients receiving an adjuvant chemoimmunotherapy program after surgery for breast carcinoma with axillary lymph node involvement, 1587

liver toxicity following treatment with *cis*-dichlorodiammineplatinum(II), 2125

methotrexate and central nervous system toxicity, 1999

noninvasive assessment of cardiac dysfunction in the cancer patient, 949

noninvasive cardiac evaluation of patients receiving adriamycin, 915

noninvasive profile in the prospective monitoring of adriamycin cardiomyopathy, 881

ophthalmologic toxicity after *cis*-dichlorodiammineplatinum(II) therapy, 1591

overview of cardiac pathology in relation to anthracycline cardiotoxicity, 955

pancytopenia induced by aminoglutethimide in the treatment of breast cancer, 1581

peripheral neuropathy as a complication of *cis*-dichlorodiammineplatinum(II) in the treatment of osteosarcoma, 819

protection against chemotherapy toxicity by iv hyperalimentation, 1139

pulmonary reaction associated with neocarzinostatin, 1271

pulmonary toxicity of antineoplastic drugs, 2003

QRS voltage change with adriamycin administration, 931

radionuclide angiography for the evaluation of anthracycline therapy, 941

a report of DL-amygdalin toxicity in two patients, 169

rhabdomyolysis as a complication of 5-azacytidine, 573

serial studies of cardiac function in patients receiving adriamycin, 923

single dose of metoclopramide in the control of vomiting from *cis*-dichlorodiammineplatinum(II), 1106

subclinical adriamycin cardiotoxicity: detection by timing the arterial sounds, 901

systemic epithelioid granulomata following immunotherapy with bacillus Calmette-Guérin, 573

symptomatic hypocalcemia following combined calcitonin and mithramycin therapy for hypercalcemia due to malignancy, 1561

systolic time intervals in monitoring adriamycin-induced cardiotoxicity, 893

systolic time intervals in monitoring for anthracycline cardiomyopathy in children, 907

tamoxifen retinopathy, 315

time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after anthracycline therapy, 945

unpredictable hematologic toxicity of weekly DDMP, 849

unusual neuromuscular toxicity after treatment of bone sarcomas with adriamycin, vincristine, and cyclophosphamide, 1408

use of the myocardial biopsy to monitor cardiotoxicity, 1607

variables for predicting serious toxicity (vinblastine dose, performance status, and prior therapeutic experience): chemotherapy for metastatic testicular cancer with *cis*-dichlorodiammineplatinum(II), vinblastine, and bleomycin, 1455

Raynaud's phenomenon, chronic bleomycin-associated, in testicular carcinoma, 570

AKR leukemia *see* Tumor systems in animals

Aminoglutethimide, pancytopenia induced by, in the treatment of breast cancer, 1581

2-Amino-1,3,4-thiadiazole, distribution and metabolism of, in mice, dogs, and monkeys, 75

Amphotericin B

and an adriamycin-containing combination chemotherapy regimen in the treatment of refractory metastatic breast cancer and sarcoma, 1565

preliminary observations on the effect of glucan in combination with, in 4 murine tumors, 1867

m-AMSA *see* Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-

DL-Amygdalin (Laetrile)

inactivity of, against human breast and colon tumor xenografts in athymic (nude) mice, 576

pharmaceutical assessment of, 99

report of toxicity in 2 patients, 169

Anaplastic 15901A mammary carcinoma *see* Tumor systems in animals

Anguidine, phase I study of, 1497

2,2'-Anhydro-1- β -D-arabinofuranosyl-5-fluorocytosine, in the treatment of advanced colorectal cancer, phase II study, 463

Aniline mustard, in mice bearing ADJ-PC5 plasmacytoma, restorative effects of levamisole on cell-mediated immune responses following chemotherapy with, 1627

Anthracyclines (*see also* Adriamycin and Daunorubicin), Proceedings of the Conference on Noninvasive and Invasive Prospective Monitoring for Anthracycline Cardiotoxicity, 855-982

Antibiotics (*see also* specific agents), empiric therapy for granulocytopenic cancer patients, 673

AraA *see* 9- β -D-Arabinofuranosyladenine

9- β -D-Arabinofuranosyladenine, effects of 2'-deoxycofomycin and erythro-9-(2-hydroxy-3-nonyl)adenine on plasma levels and urinary excretion of, in the mouse, 369

5-Azacytidine

continuous-infusion, and adriamycin in the treatment of malignant mesothelioma, 1108

pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on, in L1210 leukemic mice, 1025

rhabdomyolysis as a complication of, 573

B

Bacillus Calmette-Guérin

combined with DTIC plus actinomycin D in the treatment of disseminated malignant melanoma, 1085

combined with DTIC or DTIC, BCNU, and hydroxyurea in the treatment of stage IIIB malignant melanoma, 571

combined with MOCA (methotrexate, vincristine, cyclophosphamide, and adriamycin) for unresectable lung cancer, 681

and *Corynebacterium parvum*, *Brucella abortus* extract, glucan, levamisole, and tilorone with or without cyclophosphamide, comparative effects of, on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model, 1919
effects of, on the clearance of radiolabeled tumor cells from mouse lungs, 1873

and levamisole, effects of, on immune responses in young adult and age-immunodepressed mice, 1641

plus adriamycin, cyclophosphamide, *cis*-dichlorodiammineplatinum(II), and vincristine in the treatment of stage III lung cancer, 505

plus levamisole and surgery in the treatment of resectable lung cancer, preliminary results, 1671

pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy, 1613

plus levamisole, effects of, on immunocompetence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing radiation therapy, 1651

recurrent bladder papillomata treated with, phase I study, 551

response of disseminated breast cancer to combined

modality treatment with chemotherapy and levamisole with or without, 1685

systemic epithelioid granulomata following immunotherapy with, 573

used with chemotherapy as postoperative therapy for osteosarcoma, 213

Baker's antifol (*see also* Triazine)

in children with late-stage acute lymphocytic leukemia, 2109

phase II study of, in advanced colorectal cancer, 553

BA1112 rhabdomyosarcoma *see* Tumor systems in animals **BCNU**

combined with DTIC, hydroxyurea, and bacillus Calmette-Guérin in the treatment of stage IIIB malignant melanoma, 571

combined with 5-fluorouracil for recurrent malignant brain tumors, 2071

enhancement by hyperthermia of the effect of, against the EMT-6 mouse tumor, 439

gynecomastia after treatment with, 574

hepatic arterial, pilot clinical-pharmacologic study in patients with liver tumors, 1509

and maleic anhydride-divinyl ether (MVE), response of murine leukemia to adjuvant therapy with, and correlation with macrophage activation by MVE in the in vitro growth inhibition assay, 1807

perturbations in the cell cycle of 9L rat brain tumor cells induced by, 747

pharmacokinetics of, in man, 1305

preliminary observations on the effect of glucan in combination with, in 4 murine tumors, 1867

Benign tumors, locally aggressive, treatment of, with adriamycin plus DTIC, 167

N⁶-Benzyladenosine-5'-monophosphate, phase I study of, 1371

Bladder cancer *see* Cancer, bladder

Bleomycin

and adriamycin, phase II study in patients with multiple myeloma, 1367

combined with adriamycin, vinblastine, and DTIC and used to treat MOPP failures with Hodgkin's disease: a re-examination of goals of salvage therapy, 363

combined with *cis*-dichlorodiammineplatinum(II) and vinblastine in the treatment of testicular cancer: variables for predicting serious toxicity (vinblastine dose, performance status, and prior therapeutic experience), 1455

combined with methotrexate and streptozotocin in the treatment of epidermoid carcinoma of the lung, 155
combined with vinblastine, Raynaud's phenomenon as a side effect of treatment for testicular cancer, 569

derivatives of the bleomycin group, screening for new antitumor antibiotics, 1227

and *cis*-dichlorodiammineplatinum(II) in the treatment of esophageal cancer, 1041

epidermal cell kinetics in hairless mice after, perturbations after different single doses, 351

improved therapeutic index of, when administered by continuous-infusion in mice with Lewis lung carcinoma, 2011

- phase II trial of, in the treatment of bilharzial bladder cancer, 1109
- plus hexamethylmelamine and CCNU in patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung, 567
- Raynaud's phenomenon as a result of treatment of testicular cancer, 570
- with vinblastine, compared with vincristine, bleomycin, and actinomycin D in the treatment of disseminated germinal tumors of the testis, 129
- and vincristine, phase II study of the failure of, for previously treated children with metastatic neuroblastoma, 1201
- BM 12531**, immunomodulating effects of, in animals and tolerance in man, 1987
- B16 melanoma** *see* Tumor systems in animals
- Breast cancer** *see* Cancer, breast
- BRL 51308** (a dimethyltriazenoimidazole), antimetastatic action of, against the Lewis lung carcinoma in mice, 721
- Brucella abortus* ether extract (Bru-Pel)**
- activation of reticuloendothelial system macrophages and enhancement of host resistance to a transplantable osteogenic sarcoma in mice by, 1931
 - and *Corynebacterium parvum*, bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide, comparative effects of, on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model, 1919
 - and levamisole, comparative adjuvant effects of, in murine leukemia, 1943
 - lymphocyte stimulatory effect of, 1949
 - macrophage activation and antitumor activity of, 1937
 - overview of the activity of, 1915
- Brucella abortus* lipopolysaccharide**, macrophage activation and antitumor activity of, 1937
- Bru-Pel** *see* *Brucella abortus* ether extract
- Burkitt's lymphoma** *see* Cancer, lymphoma, Burkitt's
- BW10232 adenocarcinoma** *see* Tumor systems in animals

C

- 16/C adenocarcinoma** *see* Tumor systems in animals
- Caffeine**, and chlorpromazine, therapeutic potentiation of nitrosoureas using, in the treatment of murine tumors, 2085
- Calcitonin**, and mithramycin, symptomatic hypocalcemia following treatment for hypercalcemia due to malignancy, 1561
- Calcium leucovorin**, serum distribution of citrovorum factor and 5-methyltetrahydrofolate following oral and intravenous administration of, in normal adults, 345
- CAMP** (cyclophosphamide, adriamycin, methotrexate, and procarbazine), in the treatment of non-oat cell bronchogenic carcinoma, 1595
- Cancer** *see also* Leukemia
- anus, metastatic cloacogenic, sequential responses to adriamycin and *cis*-dichlorodiammineplatinum(II), 91
 - astrocytoma, gemistocytic, development of Hodgkin's

- disease in a patient receiving procarbazine, CCNU, and vincristine therapy for, 177
- bladder**
- bilharzial, chemotherapeutic management of: phase II trial with hexamethylmelamine and VM-26, 993
 - bilharzial, phase II trial of bleomycin in the treatment of, 1109
 - bilharzial, phase II trial of methotrexate in, 1075
 - effects of systemic administration of neocarzinostatin on, 453
 - levamisole in the treatment of, 1709
 - recurrent papillomata, treated with bacillus Calmette-Guérin: phase I trial, 551
- brain**, malignant recurrent, BCNU plus 5-fluorouracil in the treatment of, 2071
- breast**
- adriamycin and mitomycin C: possible synergistic cardiotoxicity in the treatment of, 1005
 - advanced, chromomycin A₃ in the treatment of, 19
 - advanced, 1,2:5,6-dianhydrogalactitol in the treatment of, 841
 - advanced, high-dose 6-mercaptopurine in the treatment of, 1229
 - advanced, melphalan plus methotrexate in the treatment of, 2111
 - advanced, phase II study of *cis*-dichlorodiammineplatinum(II) in the treatment of, 405
 - advanced, phase II study of triazinate and pyrazofurin in patients previously exposed to cytotoxic chemotherapy, 837
 - advanced, refractory to standard cytotoxic therapy, phase II study of mitomycin C and vinblastine in women with, 2113
 - advanced, vinblastine and 6-thioguanine in the treatment of, 1233
 - biochemical assays for the selection of cytotoxic-linked estrogens with potential therapeutic activity against, 1255
 - clinical trial of rubidazole in the treatment of, 1053
 - cycloctidine in the treatment of, 455
 - disseminated, response of, to combined modality treatment with chemotherapy and levamisole with or without bacillus Calmette-Guérin, 1685
 - early, limited treatment in the management of, 983
 - effect of primary treatment modality on the metastatic pattern of, 1275
 - levamisole as an immunoadjuvant: phase I study and application in, 1693
 - levamisole granulocytopenia in patients receiving an adjuvant chemoimmunotherapy program after surgery for, with axillary lymph node involvement, 1587
 - metastatic, activity of adriamycin in, resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (Cooper's regimen), 449
 - metastatic, association between steroid hormone receptors and response rate to cytotoxic chemotherapy in, 1281

- metastatic, massive doses of medroxyprogesterone acetate in the treatment of, 499
- metastatic, refractory, amphotericin B and an adriamycin-containing combination chemotherapy regimen in the treatment of, 1565
- pancytopenia induced by aminoglutethimide in the treatment of, 1581
- phase II study of vindesine in the treatment of, 1427
- refractory to standard cytotoxic therapy, advanced, phase II study of hexamethylmelamine in women with, 173
- stage I and II, results of primary radiation therapy for, 985
- stage II, acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for, 1135
- symmetrical mental neuropathy in, 178
- tamoxifen retinopathy in patients with, 315
- therapeutic value of mepitostane in the treatment of, 743
- use of steroids as carriers of cytotoxic agents in, 1259
- cervical
- adriamycin and methotrexate in the treatment of, 1387
 - advanced, comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of, 1435
 - squamous cell, adriamycin plus cyclophosphamide in the treatment of, 143
 - squamous cell, effects of combined immunotherapy with levamisole and bacillus Calmette-Guérin on immunocompetence of patients with, undergoing radiation therapy, 1651
- colon, human colon carcinoma and rat Walker 256 carcinosarcoma samples as in vitro predictors of clinical response to 5-fluorouracil, 1065
- colorectal
- advanced, combination of constant-infusion 5-fluorouracil, methyl-CCNU, mitomycin C, and vincristine in the treatment of, 1407
 - advanced, phase II study of 2,2'-anhydro-1- β -D-arabinofuranosyl-5-fluorocytosine in the treatment of, 463
 - advanced, phase II study of Baker's antifol in, 553
 - advanced, phase II study of metronidazole in the treatment of, 483
 - advanced, phase II trial of a combination of cyclophosphamide, vincristine, and methotrexate in the treatment of, 1203
 - advanced, phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in the treatment of, 563
 - advanced, phase II trial of maytansine in patients with, 1237
 - advanced, randomized trial of melphalan plus 5-fluorouracil versus methyl-CCNU plus 5-fluorouracil in patients with, 457
 - advanced, treatment of, with methyl-CCNU plus 5-day 5-fluorouracil infusion, 1521
 - chemotherapy for, with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil, 1603
- combination chemotherapy with 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside for, 1557
- drug-resistant, phase II study of mitomycin C, cyclophosphamide, and methotrexate in the treatment of, 549
- phase II study of melphalan in the treatment of, 1401
- phase II trial of 5-fluorouracil plus melphalan in the treatment of, 461
- untreated, phase II trial of fltorafur with mitomycin C versus fltorafur with methyl-CCNU in, 689
- esophageal
- cis*-dichlorodiammineplatinum(II) and bleomycin in the treatment of, 1041
 - effect of thymosin and irradiation on immune modulation in, 1775
- glioma, malignant, phase II study of dianhydrogalactitol in the treatment of, 1199
- granulomata, systemic epithelioid, following immunotherapy with bacillus Calmette-Guérin, 573
- gynecologic, randomized trial of CCNU compared to methyl-CCNU in the treatment of, 833
- head and neck
- effect of thymosin and irradiation on immune modulation in, 1775
 - squamous cell, effects of combined immunotherapy with levamisole and bacillus Calmette-Guérin on immunocompetence of patients with, undergoing radiation therapy, 1651
 - squamous cell, phase II trial of adriamycin and *cis*-dichlorodiammineplatinum(II) in the treatment of, 1211
 - squamous cell, randomized trial of levamisole in patients with, 1663
- histiocytoma, malignant fibrous, prolonged complete remission in, treated with adriamycin, 1405
- Hodgkin's disease
- ABVD (adriamycin, bleomycin, vinblastine, and DTIC) treatment of MOPP failures with; a re-examination of goals of salvage therapy, 363
 - development of, in a patient receiving procarbazine, CCNU, and vincristine therapy for a gemistocytic astrocytoma, 177
 - phase II clinical trial with vindesine for remission induction in: absence of cross-resistance with vincristine, 805
- large intestine, clinical trial of rubidazone in the treatment of, 1599
- liver
- hepatic arterial BCNU: pilot clinical-pharmacologic study in patients with, 1509
 - intra-arterial radionuclide infusion: a new technique to assess chemotherapy perfusion patterns, 699
 - primary, evaluation of a chemotherapeutic regimen for, in children, 1403
- lung
- adenocarcinoma, fltorafur, adriamycin, and *cis*-dichlorodiammineplatinum(II) in the treatment of, 1089
 - adenocarcinoma and large cell, mitomycin C in the treatment of, 163
 - advanced, high-dose 6-mercaptopurine in the treatment of, 1229

- advanced small cell, streptozotocin in the treatment of, 479
- advanced squamous cell and adenocarcinoma, VP-16-213 in the treatment of, 843
- advanced squamous cell, clinical trial of rubidazole in the treatment of, 1599
- clinical trial of rubidazole in the treatment of, 1053
- cis*-dichlorodiammineplatinum(II) alone followed by adriamycin and cyclophosphamide at progression versus *cis*-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for, 1207
- effects of combined immunotherapy with levamisole and bacillus Calmette-Guérin on immunocompetence of patients with, undergoing radiation therapy, 1651
- epidermoid, bleomycin, methotrexate, and streptozotocin in the treatment of, 155
- extensive non-oat cell, isophosphamide and adriamycin combined with *Corynebacterium parvum* in the treatment of, 1059
- extensive non-small cell carcinoma, adriamycin and chlorambucil versus adriamycin and thiabendazole in the treatment of, 1215
- large cell anaplastic, fluorouracil, adriamycin, and *cis*-dichlorodiammineplatinum(II) in the treatment of, 1089
- metastatic, effect of ACNU on, 139
- metastatic, phase II study of maytansine in the treatment of, 1577
- non-oat cell, cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) in the treatment of, 1595
- non-oat cell, stage III_{MO}, combined modality therapy of, 327
- oat cell, central nervous system metastases in spite of prophylactic brain irradiation, 131
- phase II study of pyrazofurin in the treatment of, 451
- primary, effect of ACNU on, 139
- resectable, final results of a multicenter placebo-controlled levamisole study of, 1677
- resectable, preliminary results of combined surgery and adjuvant bacillus Calmette-Guérin plus levamisole treatment of, 1671
- small cell anaplastic, phase II trial of streptozotocin in the treatment of, 477
- small cell, effect of thymosin in patients also receiving intensive chemotherapy, 1787
- small cell, intermittent high-dose cyclophosphamide followed by cyclophosphamide, vincristine, methotrexate, and BCNU (COMB) in the treatment of, 413
- small cell, VP-16-213 in the treatment of: a randomized trial using 3 dosage schedules, 473
- squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, hexamethylmelamine, bleomycin, and CCNU in the treatment of patients with, unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine, 567
- squamous cell, phase II trial of adriamycin and *cis*-dichlorodiammineplatinum(II) in the treatment of, 1211
- squamous cell, protection against chemotherapy toxicity by iv hyperalimentation added to *Corynebacterium parvum*, isophosphamide, and adriamycin chemoimmunotherapy for, 1139
- stage III, adriamycin, cyclophosphamide, *cis*-dichlorodiammineplatinum(II), and vincristine plus bacillus Calmette-Guérin or *Corynebacterium parvum* in the treatment of, 505
- unresectable, chemoimmunotherapy in the treatment of, 681
- lymphoma
- Burkitt's, combined modality treatment of, 2031
- malignant, clinical trial of rubidazole in the treatment of, 1053
- malignant, isophosphamide therapy for, in patients refractory to prior treatment, 493
- malignant, evaluation of VP-16-213 in the treatment of, 801
- mycosis fungoides, treatment of: effectiveness of infusions of methotrexate followed by oral citrovorum factor, 1009
- poorly differentiated lymphocytic, stage III-IV, cyclophosphamide, vincristine, and prednisone versus radiation therapy in the treatment of, 321
- non-Hodgkin's
- advanced, 5-year survey of methotrexate, cyclophosphamide, and vincristine (MEV) therapy for, 1193
- ataxia and athetosis as side effects of chemotherapy with vincristine in, 561
- phase II study of ICRF-159 in the treatment of, 465
- phase II clinical trial with vindesine for remission induction in: absence of cross-resistance with vincristine, 805
- melanoma
- advanced malignant, estramustine phosphate in the treatment of, 1329
- advanced malignant, piperazinedione in patients with, 1101
- disseminated malignant, phase II study of ICRF-159 versus combination *cis*-dichlorodiammineplatinum(II) and DTIC in, 151
- evaluation of VP-16-213 in the treatment of, 801
- malignant, cyclocytidine in the treatment of, 469
- malignant disseminated, chemoimmunotherapy (DTIC plus actinomycin D with or without bacillus Calmette-Guérin) for, 1085
- malignant, effect of levamisole as a surgical adjuvant therapy for, 1703
- malignant metastatic, human fibroblast interferon injected directly into lesions, 1899
- malignant, phase II study of vindesine in the treatment of, 1427
- malignant, stage IIIB, pilot study of adjuvant chemoimmunotherapy, 571
- metastatic malignant, phase I-II study of intermittent bolus administration of DTIC and actinomycin D in the treatment of, 1223
- metastatic malignant, phase II trial of VM-26 in the treatment of, 445
- metastatic, refractory to DTIC and a nitrosourea,

- positive phase II trial of dibromodulcitol in patients with, 2095
- thymosin-inducible lymphocytes in the peripheral blood of patients with, 1769
- mesothelioma
- effect of ACNU on, 139
 - malignant, chemotherapy for, with adriamycin and continuous infusion of 5-azacytidine, 1108
- multiple myeloma, phase II study of adriamycin and bleomycin in patients with, 1367
- neuroblastoma
- advanced, peptic hemio in the treatment of, 811
 - metastatic, failure of moderate-dose prolonged-infusion methotrexate and citrovorum factor rescue in patients with: phase II study, 1097
 - metastatic, phase II study of the failure of vincristine and bleomycin for previously treated children with, 1201
- osteosarcoma
- activity of high-dose methotrexate with citrovorum factor rescue in the treatment of, 233
 - adjuvant therapy for: preoperative and postoperative treatment, 213
 - adjuvant whole-lung radiation with or without adriamycin in the treatment of, 297
 - adriamycin, cyclophosphamide, high-dose methotrexate, and citrovorum factor in the treatment of, 251
 - advanced, *cis*-dichlorodiammineplatinum(II) in the treatment of, 239
 - bone, consideration of prognostic variables, 189
 - clinical prognostic factors in, 193
 - en bloc resections for, 225
 - high-dose cyclophosphamide, adriamycin, and high-dose methotrexate in the treatment of, 247
 - high-dose cyclophosphamide in the treatment of, 295
 - high-dose methotrexate, citrovorum factor rescue, vincristine, adriamycin, and cyclophosphamide in the treatment of, 283
 - high-dose methotrexate in the treatment of: 5-year experience, 259
 - local en bloc resection for limb preservation, 217
 - metastatic, adriamycin alone and in various combinations in the treatment of, 237
 - multidrug adjuvant chemotherapy (CONPADRI-I, CONPADRI-II, and CONPADRI-III) for, 265
 - nonmetastatic, adjuvant therapy for: an evaluation of transfer factor versus high-dose methotrexate, adriamycin, and vincristine, 289
 - overview of adjuvant treatment of, 301
 - peripheral neuropathy as a complication of *cis*-dichlorodiammineplatinum(II) in the treatment of, 819
 - primary, amputation and adriamycin in the treatment of: 5-year report, 271
 - primary operable, adjuvant treatment with adriamycin, 279
 - surgical treatment of, 205
 - treatment overview and comments on interpretation of clinical trial data, 199
- ovarian
- advanced, *cis*-dichlorodiammineplatinum(II) as third-line chemotherapy in the treatment of, 559
 - advanced *cis*-dichlorodiammineplatinum(II) in the treatment of poor-risk patients with intensive prior therapy, 555
 - advanced, *cis*-dichlorodiammineplatinum(II) plus adriamycin in the treatment of, 2027
 - advanced, recurrent after chemotherapy, adriamycin therapy for, 1375
 - cyclophosphamide, adriamycin, and *cis*-dichlorodiammineplatinum(II) in the treatment of, after failure of initial chemotherapy, 1021
 - pharmacokinetic rationale for peritoneal drug administration in the treatment of, 1
 - phase II trial of adriamycin and *cis*-dichlorodiammineplatinum(II) in the treatment of, 1211
- renal cell
- advanced, phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in the treatment of, 1093
 - metastatic, chemohormonal therapy for, with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate, 1379
- sarcoma
- amphotericin B and an adriamycin-containing combination chemotherapy regimen in the treatment of, 1565
 - bone, unusual neuromuscular toxicity after treatment with adriamycin, vincristine, and cyclophosphamide, 1408
 - metastatic, acute myelomonocytic leukemia following a chemotherapeutic regimen (cyclophosphamide, vincristine, adriamycin, and DTIC) for, 1513
 - metastatic, phase II study of pyrazofurin in the treatment of, 1573
- squamous cell, miscellaneous carcinomas, phase II trial of adriamycin and *cis*-dichlorodiammineplatinum(II) in the treatment of, 1211
- stomach, advanced, 5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of, 1287
- testicular
- combination chemotherapy with *cis*-dichlorodiammineplatinum(II) and adriamycin for, refractory to vinblastine and bleomycin, 1351
 - disseminated germinal, comparison of vinblastine and bleomycin with vincristine, bleomycin, and actinomycin D, 129
 - metastatic, *cis*-dichlorodiammineplatinum(II), vinblastine, and bleomycin in the treatment of: variables for predicting serious toxicity (vinblastine dose, performance status, and prior therapeutic experience), 1455
 - phase II trial of adriamycin and *cis*-dichlorodiammineplatinum(II) in the treatment of, 1211
 - Raynaud's phenomenon as a result of bleomycin administration, 570
 - Raynaud's phenomenon as a side effect of chemotherapy with bleomycin and vinblastine, 569
 - thymoma, invasive, responsive to oral corticosteroids, 1397

- uterine, advanced, endometrial, adriamycin compared with cyclophosphamide in the treatment of, 159
- Carboxypeptidase G_{II}**, and citrovorum factor, comparative effects of, on cerebrospinal fluid-methotrexate pharmacokinetics, 1549
- Cardiotoxicity** *see* Adverse effects in man
- CB 10286** (a benzoid dimethyltriazeno), antimetastatic action of, against the Lewis lung carcinoma in mice, 721
- CCNU**
combined with 5-fluorouracil and cyclophosphamide in the treatment of colorectal carcinoma: comparison of oral and continuous iv administration of 5-fluorouracil, 1603
compared to methyl-CCNU, a randomized trial in the treatment of gynecologic cancer, 833
given with vincristine and procarbazine, development of Hodgkin's disease in a patient being treated for gemistocytic astrocytoma, 177
plus hexamethylmelamine and bleomycin in patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung, 567
- CD8F₁ mammary adenocarcinoma** *see* Tumor systems in animals
- Cell kinetics**, and chemotherapy: a critical review, 1117
- Cell lines**
BCNU-induced perturbations in the cell cycle of 9L rat brain tumor cells, 747
Chinese hamster cells, protective effect of hyperthermia against the cytotoxicity of actinomycin D on, 1489
comparison of metoprine and etoprine by measuring the inhibition of deoxyuridine incorporation into the DNA of human leukemic cells, 341
cross-linking of DNA in L1210 cells (LS2 plus LM4 lines) and nuclei treated with cyclophosphamide and phosphoramidate mustard, 23
cytologic evidence that taxol acts as a mitotic spindle poison using P388 leukemia cells, 1219
human breast cancer, use of, for the evaluation of cytotoxic agents linked to hormones, 1267
inhibitory effect of hydroxynitrodihydrothymine on the growth of Ehrlich ascites tumor cells, 823
intracellular localization of *meso*-tetra(*p*-sulphophenyl)porphine, a potential tumor localizing agent, using Vero and HEp-2 cells in vitro, 511
kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells, 1313
Lewis lung cells cultured with activated macrophages, potential mechanism of macrophage-mediated tumor cell cytotoxicity, 1823
perturbed cell kinetics of 9L rat brain tumor cells following dianhydrogalactitol, 2055
solid rat Walker 256 carcinosarcoma and human colon carcinoma, effects of 5-fluorouracil on: evaluation as in vitro predictors of clinical response, 1065
- Central nervous system**, metastases in patients with oat cell carcinoma of the lung, in spite of prophylactic brain irradiation, 131
- Cephalothin**, combined with gentamicin, acute renal failure after *cis*-dichlorodiammineplatinum(II) and, 693
- Cervical cancer** *see* Cancer, cervical
- 6C3HED lymphosarcoma** *see* Tumor systems in animals
- Chlorambucil**
acute leukemia after prolonged immunosuppressive therapy for glomerulonephritis, 1110
acute myelogenous leukemia in patients receiving, as long-term adjuvant chemotherapy for stage II breast cancer, 1135
and adriamycin versus adriamycin and thiabendazole in the treatment of extensive non-small cell carcinoma of the lung, 1215
- Chlorozotocin**
disposition of, in rats and dogs, 31
pharmacologic disposition of, in mice, 1145
- Chlorpromazine**, and caffeine, therapeutic potentiation of nitrosoureas using, in the treatment of murine tumors, 2085
- Choriocarcinoma**, human, relationship between plasma levels of chorionic gonadotropin and tumor growth during chemotherapy for, maintained in the hamster cheek pouch, 2101
- Chromomycin A₃**, in the treatment of advanced breast cancer, 19
- Chronochemotherapy**, with cytosine arabinoside or cyclophosphamide in L1210 leukemic mice, 1337
- Citrovorum factor**
and carboxypeptidase G_{II}, comparative effects of, on cerebrospinal fluid-methotrexate pharmacokinetics, 1549
and high-dose methotrexate, phase II clinical trial with, in patients with various tumors, 1295
and moderate-dose prolonged-infusion methotrexate, failure of, in patients with previously treated metastatic neuroblastoma: phase II study, 1097
oral, effectiveness of infusions of methotrexate followed by, in the treatment of mycosis fungoides lymphoma, 1009
plus adriamycin, cyclophosphamide, and high-dose methotrexate in the treatment of osteosarcoma, 251
rescue, and high-dose methotrexate, vincristine, adriamycin, and cyclophosphamide in the treatment of osteosarcoma, 283
rescue, modified, phase I trial of high-dose methotrexate in advanced metastatic malignancies, 397
rescue, with high-dose methotrexate in the treatment of osteosarcoma and other malignancies, 233
rescue, with methotrexate as postoperative therapy for osteosarcoma, alternated with adriamycin, 213
rescue, used with methotrexate and vincristine, with or without adriamycin, as preoperative therapy for osteosarcoma, 217
serum distribution of, and 5-methyltetrahydrofolate following oral and im administration of calcium leucovorin in normal adults, 345
- Clinical trials**, sample size requirements for evaluating a conservative therapy, 1037
- Coenzyme Q₁₀**, adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by, 887
- Colon adenocarcinoma (CX-2)** *see* Tumor systems in animals

- Colon adenocarcinoma (MAC-15A)** *see* Tumor systems in animals
- Colon cancer** *see* Cancer, colon
- Colorectal cancer** *see* Cancer, colorectal
- COMB** (cyclophosphamide, vincristine, methotrexate, and BCNU), used after high-dose cyclophosphamide in the treatment of small cell lung cancer, 413
- Combination chemotherapy** (*see also* individual drug names), arriving at optimal treatment levels by incorporating side effect constraints, 333
- COMPADRI-II** (cyclophosphamide, vincristine, melphalan, adriamycin, and high-dose methotrexate), for osteosarcoma, 265
- COMPADRI-III** (cyclophosphamide, vincristine, melphalan, adriamycin [intensified dose], and high-dose methotrexate), for osteosarcoma, 265
- Computerized chest tomography**, surgically proven pulmonary metastases not demonstrated by, 1404
- CONPADRI-I** (cyclophosphamide, vincristine, melphalan, and adriamycin), for osteosarcoma, 265
- Cooper's regimen** (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone), activity of adriamycin in metastatic breast cancer resistant to, 449
- Corticosteroids**, oral, invasive thymoma responsive to, 1397
- Corynebacterium parvum***
and *Brucella abortus* extract, bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide, comparative effects of, on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model, 1919
combined with isophosphamide and adriamycin in the treatment of extensive non-oat cell lung cancer, 1059
combined with MOCA (methotrexate, vincristine [Oncovin], cyclophosphamide, and adriamycin) for unresectable lung cancer, 681
effect of, on the clearance of radiolabeled tumor cells from mouse lungs, 1873
plus adriamycin, cyclophosphamide, *cis*-dichlorodiammineplatinum(II), and vincristine in the treatment of stage III lung cancer, 505
used with isophosphamide, adriamycin, and iv hyperalimentation for squamous cell lung cancer, 1139
- Cycloctidine**
in the treatment of breast cancer, 455
in the treatment of malignant melanoma, 469
- Cyclophosphamide**
and adriamycin and vincristine, unusual neuromuscular toxicity after treatment of bone sarcomas, 1408
as a cause of acute hypersensitivity reaction: possible lack of cross-sensitivity to mechlorethamine and isophosphamide, 180
chronochemotherapy in L1210 leukemic mice, 1337
combined with adriamycin, methotrexate, procarbazine, and radiation therapy in the treatment of stage III_{non} non-oat cell lung cancer, 327
combined with adriamycin, methotrexate, and procarbazine (CAMP) in the treatment of non-oat cell bronchogenic carcinoma, 1595
combined with adriamycin and *cis*-dichlorodiammineplatinum(II) in the treatment of ovarian cancer after failure of initial chemotherapy, 1021
combined with 5-fluorouracil and CCNU in the treatment of colorectal cancer: comparison of oral and continuous iv administration of 5-fluorouracil, 1603
combined with methotrexate and vincristine (MEV) in the treatment of advanced non-Hodgkin's lymphomas: 5-year survey, 1193
combined with methotrexate, vincristine, and adriamycin (MOCA) with or without bacillus Calmette-Guérin or *Corynebacterium parvum* in the treatment of unresectable lung cancer, 681
combined with vincristine and methotrexate, phase II trial in the treatment of advanced colorectal carcinoma, 1203
combined with vincristine and methotrexate, prophylactic intrathecal methotrexate, and postinduction whole-abdomen radiotherapy for Burkitt's lymphoma, 2031
combined with vincristine and prednisone versus radiation therapy in the treatment of stage III-IV poorly differentiated lymphocytic lymphoma, 321
comparative effects of *Corynebacterium parvum*, *Brucella abortus* extract, bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without, on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model, 1919
compared with adriamycin in the treatment of advanced endometrial cancer, 159
comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of cervical cancer, 1435
cis-dichlorodiammineplatinum(II) alone followed by adriamycin and cyclophosphamide at progression versus *cis*-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for lung cancer, 1207
and high-dose methotrexate, citrovorum factor rescue, vincristine, and adriamycin in the treatment of osteosarcoma, 283
high-dose, in the treatment of osteosarcoma, 295
high-dose, with adriamycin and high-dose methotrexate in the treatment of osteosarcoma, 247
intermittent, high-dose, followed by cyclophosphamide, vincristine, methotrexate, and BCNU (COMB) in the treatment of small cell carcinoma of the lung, 413
metabolites of, comparative disposition of, in the mouse using the *Salmonella*/mutagenesis assay, 1321
as part of the multidrug adjuvant chemotherapy (CONPADRI-I, COMPADRI-II, and COMPADRI-III) for osteosarcoma, 265
plus adriamycin, high-dose methotrexate, and citrovorum factor in the treatment of osteosarcoma, 251
plus adriamycin, *cis*-dichlorodiammineplatinum(II), vincristine, and bacillus Calmette-Guérin or *Corynebacterium parvum* in the treatment of stage III lung cancer, 505
plus adriamycin in the treatment of squamous cell carcinoma of the cervix, 143
plus mitomycin C and methotrexate, phase II study of, in drug-resistant colorectal cancer, 549
and phosphoramidate mustard, cross-linking of DNA in

L1210 cells (LS2 and LM4 lines) and nuclei treated with, 23
 therapeutic implications of cell kinetic changes after, in "spontaneous" and "transplantable" mammary tumors, 727
Cytomabena, phase I-II and oral absorption studies of, 401
Cytosine arabinoside
 chronochemotherapy in L1210 leukemic mice, 1337
 combined with 5-fluorouracil, mitomycin C, and adriamycin in the treatment of colorectal cancer, 1557
 combined with vincristine and prednisone in the treatment of adult acute lymphoblastic leukemia, 1389
 influence of continuous infusion of, on sequencing with daunorubicin in L1210 leukemia, 547

D

Daunorubicin

influence of continuous infusion of cytosine arabinoside on sequencing with, in L1210 leukemia, 547
 overview of cardiac pathology in relation to anthracycline cardiotoxicity, 955
 systolic time intervals in monitoring for cardiomyopathy in children receiving, 907
 time- and dose-dependence changes in ejection fraction determined by radionuclide angiography after therapy with, 945

DDEP [2,4-diamino-5-(3',4'-dichlorophenyl)-6-ethylpyrimidine] *see* Etoprine

DDMP [2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine] *see* Metoprine

10-Deaza-aminopterin, antitumor properties of, in mice, 1047

4-Demethoxyadriamycin, synthesis and antitumor activity of, in animals, 375

4-Demethoxy-4'-epiadriamycin, synthesis and antitumor activity of, in animals, 375

2'-Deoxycofomycin

and erythro-9-(2-hydroxy-3-nonyl)adenine, effects of, on plasma levels and urinary excretion of 9- β -D-arabino-furanosyladenine in the mouse, 369
 use of microbiologic and enzymatic assays in studies on the disposition of, in the mouse, 1153

β -2'-Deoxythioguanosine, antileukemic therapy and toxicology studies in mice with, 135

Desacetyl vinblastine amide sulfate *see* Vindesine

1,2:5,6-Dianhydrogalactitol

perturbed cell kinetics of 9L rat brain tumor cells following, 2055
 phase II study of, in the treatment of malignant glioma, 1199
 studies on the distribution of, into the central nervous system of the rat, 409
 in the treatment of advanced breast cancer, 841

Dibromodulcitol, positive phase II trial of, in patients with metastatic melanoma refractory to DTIC and a nitrosourea, 2095

cis-Dichlorodiammineplatinum(II)

and adriamycin in the treatment of testicular cancer refractory to vinblastine and bleomycin, 1351

and adriamycin, phase II trial in the treatment of squamous cell, ovarian, and testicular carcinomas, 1211

and adriamycin, sequential responses in metastatic cloacogenic carcinoma of the anus, 91

alone and combined with sarcosyl in the treatment of transplantable mouse tumors, 705

alone followed by adriamycin and cyclophosphamide at progression versus *cis*-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for lung cancer, 1207

and bleomycin in the treatment of esophageal cancer, 1041

a case of liver toxicity following treatment with, 2125

combined with adriamycin and fltorafur in the treatment of adenocarcinoma and large cell anaplastic carcinoma of the lung, 1089

combined with cyclophosphamide and adriamycin in the treatment of ovarian cancer after failure of initial chemotherapy, 1021

combined with DTIC versus ICRF-159 in patients with disseminated malignant melanoma, phase II study, 151

combined with vinblastine and bleomycin in the treatment of testicular cancer: variables for predicting serious toxicity (vinblastine dose, performance status, and prior therapeutic experience), 1455

and gentamicin-cephalothin, acute renal failure after, in advanced solid tumors, 693

instability of, in dextrose solution, 1105

ophthalmologic toxicity after therapy with, 1591

peripheral neuropathy as a complication of, in the treatment of osteosarcoma, 819

phase I-II study of, given by continuous iv infusion in the treatment of solid tumors, 1553

phase II study in the treatment of advanced breast cancer, 405

plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of, in man, 1359

plus adriamycin, cyclophosphamide, vincristine, and bacillus Calmette-Guérin or *Corynebacterium parvum* in the treatment of stage III lung cancer, 505

plus adriamycin in the treatment of advanced ovarian cancer, 2027

single dose of metoclopramide in the control of vomiting from, in man, 1106

as third-line chemotherapy, in advanced ovarian adenocarcinoma, 559

in the treatment of advanced osteosarcoma, 239

in the treatment of advanced ovarian cancer in poor-risk patients with intensive prior therapy, 555

Diffusion chamber-cultivated cells, attempted drug-tumor sensitivity matching using, 2035

DIVEMA *see* Maleic anhydride-divinyl ether

DNA synthesis, rate of, as an indication of drug toxicity and as a guide for scheduling cancer therapy, 755

DTIC

and actinomycin D, phase I-II study of, intermittent bolus administration, in metastatic malignant melanoma, 1223

and actinomycin D with or without bacillus Calmette-Guérin in the treatment of disseminated malignant melanoma, 1085

antimetastatic action of, against the Lewis lung carcinoma in mice, 721

combined with adriamycin, bleomycin, and vinblastine and used to treat MOPP failures with Hodgkin's disease: a re-examination of goals of salvage therapy, 363

combined with adriamycin, in the treatment of benign and locally aggressive tumors, 167

combined with bacillus Calmette-Guérin alone or bacillus Calmette-Guérin, BCNU, and hydroxyurea in the treatment of stage IIIB malignant melanoma, 571

combined with *cis*-dichlorodiammineplatinum(II) versus ICRF-159 in patients with disseminated malignant melanoma, phase II study, 151

E

EMT-6 mouse tumor *see* Tumor systems in animals

Erythro-9-(2-hydroxy-3-nonyl)adenine, and 2'-deoxycofomycin, effects of, on plasma levels and urinary excretion of 9- β -D-arabinofuranosyladenine in the mouse, 369

Esophageal cancer *see* Cancer, esophageal

Estracyt *see* Estramustine phosphate

Estramustine phosphate, in the treatment of advanced malignant melanoma, 1329

Estrogen receptors, association between, and response rate to cytotoxic chemotherapy in metastatic breast cancer, 1281

Etoprime, comparison with metoprime by measuring the inhibition of deoxyuridine incorporation into the DNA of human leukemic cells, 341

F

5-Fluorouracil

combined with BCNU for recurrent malignant brain tumors, 2071

combined with cyclophosphamide and CCNU in the treatment of colorectal cancer: comparison of oral and continuous iv administration of, 1603

combined with methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced stomach cancer, 1287

combined with mitomycin C, adriamycin, and cytosine arabinoside in the treatment of colorectal cancer, 1557

constant-infusion, combined with methyl-CCNU, mitomycin C, and vincristine in the treatment of advanced colorectal carcinoma, 1407

5-day infusion, plus methyl-CCNU in the treatment of advanced colorectal cancer, 1521

effects of, on human colon carcinoma and solid rat Walker 256 carcinosarcoma: evaluation as in vitro predictors of clinical response, 1065

phase II trial of, combined with melphalan, in the treatment of colorectal cancer, 461

plus adriamycin and mitomycin C, phase II trial in advanced colorectal cancer, 563

plus melphalan versus methyl-CCNU and 5-fluorouracil in a randomized trial in patients with advanced colorectal cancer, 457

qualitative and quantitative toxicity of single and sequential sublethal doses of, in BDF₁ mice, 533

Florafur

combined with adriamycin and *cis*-dichlorodiammineplatinum(II) in the treatment of adenocarcinoma and large cell anaplastic carcinoma of the lung, 1089

with mitomycin C versus florafur with methyl-CCNU in untreated colorectal cancer, phase II trial, 689

Fucosyltransferases, plasma, levels of, as an index of disease status in acute myelogenous leukemia, 147

Fungal metabolites, antitumor activity of verrucarins β -9,10-epoxides, 1585

G

Gallium nitrate, phase I study of, 1449

Gentamicin, combined with cephalothin, acute renal failure after *cis*-dichlorodiammineplatinum(II) and, 693

Glucan

and *Corynebacterium parvum*, *Brucella abortus* extract, bacillus Calmette-Guérin, levamisole, and tilorone with or without cyclophosphamide, comparative effects of, on tumor growth macrophage production, and macrophage cytotoxicity in a murine mammary tumor model, 1919

effect of, on the clearance of radiolabeled tumor cells from mouse lungs, 1873

inhibition of tumor growth and enhancement of survival in 4 syngeneic murine tumor models, 1857

preliminary observations on the effect of, in combination with radiation and chemotherapy in 4 murine tumors, 1867

a successful alternative to dexamethasone for patients receiving brain irradiation for metastatic disease, 1081

Granuloma *see* Cancer, granulomata

Gross leukemia *see* Tumor systems in animals

Gynecologic cancer *see* Cancer, gynecologic

H

Hexamethylmelamine

plus bleomycin and CCNU in patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung, 567

variable oral absorption of, in man, 2117

and VM-26, a phase II trial in the chemotherapeutic management of bilharzial bladder cancer, 993

in women with advanced breast cancer refractory to standard cytotoxic therapy, phase II study, 173

Histiocytoma *see* Cancer, histiocytoma

Hodgkin's disease *see* Cancer, Hodgkin's disease

Hoechst 33342, alteration of binding of, to human leukemic cells by adriamycin, 1393

Human bladder tumors *see* Tumor systems in animals

Human breast carcinoma (MX-1) *see* Tumor systems in animals

Hycanthone, phase I study of, 1173

7-Hydroxymethotrexate

and methotrexate, analysis of, by high-pressure liquid chromatography, 529

and methotrexate, high-pressure liquid chromatographic determination of, in human plasma, 381

Hydroxynitrodihydrothymine, inhibitory effect of, on the growth of Ehrlich ascites tumor cells, 823

Hydroxyurea

and adriamycin, vinblastine, and medroxyprogesterone acetate, chemohormonal therapy for metastatic renal cell carcinoma, 1379

combined with DTIC, BCNU, and bacillus Calmette-Guérin in the treatment of stage IIIB malignant melanoma, 571

Hyperalimentation, iv, protection against chemotherapy toxicity by, 1139

Hyperbaric hydrogen, response of 5 established solid transplantable mouse tumors and 1 mouse leukemia to, 1077

Hypercalcemia, due to malignancy, symptomatic hypocalcemia following combined calcitonin and mithramycin therapy for, 1561

Hyperthermia

protective effect of, against the cytotoxicity of actinomycin D on Chinese hamster cells, 1489

used to enhance the effect of BCNU against the EMT-6 mouse tumor, 439

ICRF-159

phase II study of, in non-Hodgkin's lymphomas, 465

versus *cis*-dichlorodiammineplatinum(II) plus DTIC in patients with disseminated malignant melanoma, phase II study, 151

Immunomodulation *see* Proceedings of the 4th Conference on Immune Modulation and Control of Neoplasia, 1611-1996

Immunotherapy

bacillus Calmette-Guérin combined with DTIC or DTIC, BCNU, and hydroxyurea in the treatment of stage IIIB malignant melanoma, 571

bacillus Calmette-Guérin or *Corynebacterium parvum* combined with MOCA (methotrexate, vincristine, cyclophosphamide, and adriamycin) for unresectable lung cancer, 681

bacillus Calmette-Guérin or *Corynebacterium parvum* with combination chemotherapy (adriamycin, cyclophosphamide, *cis*-dichlorodiammineplatinum[II], and vincristine) in stage III lung cancer, 505

bacillus Calmette-Guérin plus DTIC and actinomycin D in the treatment of disseminated malignant melanoma, 1085

Corynebacterium parvum plus isophosphamide and adriamycin in the treatment of extensive non-oat cell lung cancer, 1059

Corynebacterium parvum used with isophosphamide, adriamycin, and iv hyperalimentation for squamous cell lung cancer, 1139

effects of combined immunotherapy with levamisole and bacillus Calmette-Guérin on immunocompetence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing radiation therapy, 1651

levamisole as an immunoadjuvant: phase I study and application in breast cancer, 1693

levamisole granulocytopenia in patients receiving an adjuvant chemoimmunotherapy program after surgery for breast carcinoma with axillary lymph node involvement, 1587

pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy, 1613

phase I-II trials of poly IC stabilized with poly-L-lysine, 1907

Proceedings of the 4th Conference on Immune Modulation and Control of Neoplasia, 1611-1996

preliminary report of the use of levamisole in the treatment of bladder cancer, 1709

randomized trial of levamisole in patients with squamous cancer of the head and neck, 1663

recurrent bladder papillomata treated with bacillus Calmette-Guérin: phase I trial, 551

response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without bacillus Calmette-Guérin, 1685

a review of immunologic properties and efficacy of thiabendazole in combined modality cancer therapy, 1955

systemic epithelioid granulomata following immunotherapy with bacillus Calmette-Guérin, 573

transfer factor compared to combination chemotherapy (high-dose methotrexate, adriamycin, and vincristine) in the treatment of nonmetastatic osteosarcoma, 289

Indoloquinolinones, regression of 180J sarcoma after treatment with substituted, 1575

Interferon

antitumor activity of, against murine osteogenic sarcoma in vitro and in vivo, 1881

cytotoxic activity of macrophages treated with, studied by various inhibitors, 1889

human, and its inducers, clinical overview, 1897

human fibroblast, in human neoplasia, 1899

isoprinosine used to increase the antitumor action of, 1971

role of, in augmentation of natural and antibody-dependent cell-mediated cytotoxicity, 1893

Isophosphamide

combined with adriamycin and *Corynebacterium parvum* in the treatment of extensive non-oat cell lung cancer, 1059

for hematologic malignancies in patients refractory to prior treatment, 493

used with *Corynebacterium parvum*, adriamycin, and iv hyperalimentation for squamous cell lung cancer, 1139

Isoprinosine

and levamisole, muramyl dipeptide, and SM1213, effects

of, on lymphocyte and macrophage function in vitro, 1981
an overview, 1963
preliminary characterization in mice of the effect of, on the immune system, 1975
used to increase the antitumor action of interferon, 1971

J

Jensen sarcoma *see* Tumor systems in animals
180J sarcoma *see* Tumor systems in animals

K

KHT fibrosarcoma *see* Tumor systems in animals

L

Laetrile *see* DL-Amygdalin
L1210 Cr leukemia *see* Tumor systems in animals
Leucovorin *see* Citrovorum factor
Leukemia
acute
adult, lymphoblastic, combination therapy with cytosine arabinoside, vincristine, and prednisone in, 1389
after prolonged immunosuppressive therapy for glomerulonephritis, 1110
isophosphamide therapy for, in patients refractory to prior treatment, 493
lymphocytic
childhood, actinomycin D in the treatment of, 829
late-stage, Baker's antifol in children with, 2109
myelogenous
levels of two plasma fucosyltransferases as an index of disease status in, 147
in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer, 1135
refractory, phase I study of pyrazofurin in the treatment of, 1569
myelomonocytic, following a chemotherapeutic regimen (cyclophosphamide, vincristine, adriamycin, and DTIC) for metastatic sarcoma, 1513
phase I study of neocarzinostatin in patients with, 1363
phase II clinical trial with vindesine for remission induction in: absence of cross-resistance with vincristine, 805
chronic myeloid, blastic crisis of, phase II clinical trial with vindesine for remission induction in: absence of cross-resistance with vincristine, 805
Levamisole
adverse reactions to, 1721
in autoimmune disease, correlations of clinical and laboratory effects of treatment with, 1715

and bacillus Calmette-Guérin, effects of, on immune responses in young adult and age-immunodepressed mice, 1641
and *Brucella abortus*, comparative adjuvant effects of, in murine leukemia, 1943
causing granulocytopenia in patients receiving an adjuvant chemoimmunotherapy program after surgery for breast cancer with axillary lymph node involvement, 1587
and chemotherapy, response of disseminated breast cancer to combined modality treatment, with or without bacillus Calmette-Guérin, 1685
and *Corynebacterium parvum*, *Brucella abortus* extract, bacillus Calmette-Guérin, glucan, and tilorone with or without cyclophosphamide, comparative effects of, on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model, 1919
effect of, as a surgical adjuvant therapy for malignant melanoma, 1703
effect of, on the metabolism of phagocytic cells, 1637
final results of a multicenter placebo-controlled study of, in resectable lung cancer, 1677
as an immunoadjuvant: phase I study and application in breast cancer, 1693
immunopotential and tumor inhibition with, 1623
and isoprinosine, muramyl dipeptide, and SM1213, effects of, on lymphocyte and macrophage function in vitro, 1981
plus adjuvant bacillus Calmette-Guérin and surgery in the treatment of resectable lung cancer, preliminary results of, 1671
plus bacillus Calmette-Guérin, effects of, on immunocompetence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing radiation therapy, 1651
randomized trial of, in patients with squamous cancer of the head and neck, 1663
restorative effects of, on cell-mediated immune responses following chemotherapy with aniline mustard in mice bearing ADJ-PC5 plasmacytoma, 1627
in the treatment of bladder cancer, 1709
Lewis lung carcinoma *see* Tumor systems in animals
L1210 Ha leukemia *see* Tumor systems in animals
Liver cancer *see* Cancer, liver
Liver scanning, in patients with malignancy: rationale, results, and limitations, 1183
L1210 leukemia *see* Tumor systems in animals and Cell lines
LSTRA lymphoma *see* Tumor systems in animals
Lung cancer *see* Cancer, lung
Lymphoma *see* Cancer, lymphoma
Lymphosarcoma *see* Cancer, lymphosarcoma

M

MAC-15A transplantable colon ascites adenocarcinoma *see* Tumor systems in animals
109 Madison lung carcinoma (M109) *see* Tumor systems in animals

Maleic anhydride-divinyl ether (MVE)

- and BCNU, response of murine leukemia to adjuvant therapy with, and correlation with macrophage activation by MVE in the in vitro growth inhibition assay, 1807
- cell and tissue distribution of ¹⁴C-labeled, 1846
- effect of, on experimental M109 metastases and macrophage tumoricidal function, 1817
- effect of, on the lymphocyte subpopulations of tumor-bearing, irradiated mice, 1831
- future direction of synthetic polyanions (pyran copolymer), 1853
- linked with methotrexate: immune adjuvant role of polymeric carriers linked to antitumor agents, 1837
- polyanions, relationship of molecular weight to antiviral and antitumor activities and toxic effects of, 1797
- therapeutic activity of, against spontaneous, autochthonous murine mammary tumors, 1791

Mammary carcinoma *see* Tumor systems in animals

Maytansine

- initial clinical trials of, 429
- phase I study of, 435
- phase I study of, using a 3-day schedule in advanced malignancies, 425
- phase II evaluation of, in the treatment of metastatic lung cancer, 1577
- phase II trial of, in patients with advanced colorectal carcinoma, 1237

Medroxyprogesterone acetate

- adriamycin, hydroxyurea, and vinblastine, chemohormonal therapy for metastatic renal cell carcinoma, 1379
- massive doses, in the treatment of metastatic breast cancer, 499
- plus vinblastine and methyl-CCNU in the treatment of advanced renal cell cancer: phase II study, 1093

Melanoma *see* Cancer, melanoma

Melphalan

- as part of the multidrug adjuvant chemotherapy (CONPADRI-I, CONPADRI-II, and CONPADRI-III) for osteosarcoma, 265
- phase II study of, in the treatment of colorectal carcinoma, 1401
- phase II trial of, combined with 5-fluorouracil, in the treatment of colorectal cancer, 461
- plus 5-fluorouracil versus methyl-CCNU plus 5-fluorouracil in a randomized trial in patients with advanced colorectal cancer, 457
- plus methotrexate in the treatment of advanced breast cancer, 2111

Mepitiostane, therapeutic value of, in the treatment of advanced breast cancer, 743

6-Mercaptopurine, high-dose, in the treatment of advanced refractory cancer, 1229

Mesothelioma *see* Cancer, mesothelioma

Meth A sarcoma *see* Tumor systems in animals

Methanesulfonamide, *N*-[4-(9-acridinylamino)-3-methoxyphenyl]- (*m*-AMSA), phase I study of, using a single-dose schedule, 1421

Methotrexate

- and central nervous system toxicity, 1999
- and citrovorum factor rescue, as postoperative therapy for osteosarcoma, alternated with adriamycin, 213
- combined with adriamycin in the treatment of cervical carcinoma, 1387
- combined with cyclophosphamide, adriamycin, procarbazine, and radiation therapy in the treatment of stage III_{M0} non-oat cell lung cancer, 327
- combined with cyclophosphamide, adriamycin, and procarbazine (CAMP) in the treatment of non-oat cell bronchogenic carcinoma, 1595
- combined with cyclophosphamide and vincristine (MEV) in the treatment of advanced non-Hodgkin's lymphomas: 5-year survey, 1193
- combined with cyclophosphamide and vincristine, phase II trial in the treatment of advanced colorectal carcinoma, 1203
- combined with cyclophosphamide and vincristine, prophylactic intrathecal methotrexate, and postinduction whole-abdomen radiotherapy for Burkitt's lymphoma, 2031
- combined with streptozotocin and bleomycin in the treatment of epidermoid carcinoma of the lung, 155
- combined with vincristine, cyclophosphamide, and adriamycin (MOCA) with or without bacillus Calmette-Guérin or *Corynebacterium parvum* in the treatment of unresectable lung cancer, 681
- comparative effects of citrovorum factor and carboxypeptidase G₁ on cerebrospinal fluid-methotrexate pharmacokinetics, 1549
- effectiveness of infusions of, followed by oral citrovorum factor in the treatment of mycosis fungoides lymphoma, 1009
- high-dose, activity of, with citrovorum factor rescue in the treatment of osteosarcoma and other malignancies, 233
- high-dose, and citrovorum factor rescue, phase II clinical trial in patients with various tumors, 1295
- high-dose, and citrovorum factor rescue, vincristine, adriamycin, and cyclophosphamide in the treatment of osteosarcoma, 283
- high-dose, not a conventional treatment, 178
- high-dose, phase I trial of, with modified citrovorum factor rescue in the treatment of advanced metastatic malignancies, 397
- high-dose, plus adriamycin, cyclophosphamide, and citrovorum factor in the treatment of osteosarcoma, 251
- high-dose, plus vincristine and adriamycin versus transfer factor in the treatment of nonmetastatic osteosarcoma, 289
- high-dose, studies of, in osteosarcoma: historical background, 307
- high-dose, in the treatment of osteosarcoma, 5-year experience, 259
- high-dose, with adriamycin and high-dose cyclophosphamide in the treatment of osteosarcoma, 247
- and 7-hydroxymethotrexate, analysis of, by high-pressure liquid chromatography, 529
- and its major metabolite, 7-hydroxymethotrexate, high-pressure liquid chromatographic determination of, in human plasma, 381

- linked with maleic anhydride-divinyl ether: immune adjuvant role of polymeric carriers linked to antitumor agents, 1837
- moderate-dose prolonged-infusion, plus citrovorum factor rescue, failure of in patients with previously treated metastatic neuroblastoma: phase II study, 1097
- parenteral dosage forms, separation and identification of impurities in, 13
- as part of the multidrug adjuvant chemotherapy (COMPADRI-II and COMPADRI-III) for osteosarcoma, 265
- phase II trial of, in the treatment of carcinoma of the bilharzial bladder, 1075
- plus melphalan in the treatment of advanced breast cancer, 2111
- plus mitomycin C and cyclophosphamide, phase II study of, in drug-resistant colorectal cancer, 549
- probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs, 1465
- purity of various samples of, 487
- relationship between plasma levels of chorionic gonadotropin and tumor growth during chemotherapy with, in human choriocarcinoma maintained in the hamster cheek pouch, 2101
- used with citrovorum factor rescue and vincristine, with or without adriamycin, as preoperative therapy for osteosarcoma, 217
- and vincristine, lack of synergism between, in L1210 murine leukemia in vivo, 997
- Methyl-CCNU**
- combined with constant-infusion 5-fluorouracil, mitomycin C, and vincristine in the treatment of advanced colorectal carcinoma, 1407
- combined with 5-fluorouracil, adriamycin, and mitomycin C in the treatment of advanced stomach cancer, 1287
- compared to CCNU, a randomized trial in the treatment of gynecologic cancer, 833
- interstitial pulmonary fibrosis as a complication of prolonged therapy with, 1355
- phase II trial of fluorouracil with mitomycin C versus fluorouracil with methyl-CCNU in untreated colorectal cancer, 689
- plus 5-day 5-fluorouracil infusion in the treatment of advanced colorectal cancer, 1521
- plus 5-fluorouracil versus melphalan and 5-fluorouracil in a randomized trial in patients with advanced colorectal cancer, 457
- plus vinblastine and medroxyprogesterone in the treatment of advanced renal cell cancer: phase II study, 1093
- 5-Methyltetrahydrofolate**, serum distribution of, and citrovorum factor following oral and im administration of calcium leucovorin in normal adults, 345
- Metoclopramide**, single dose of, in the control of vomiting from *cis*-dichlorodiammineplatinum(II) in man, 1106
- Metoprine**
- comparison with etoprine by measuring the inhibition of deoxyuridine incorporation into the DNA of human leukemic cells, 341
- weekly, unpredictable hematologic toxicity of, 849
- Metronidazole**
- in cancer therapy, 1270, 1271
- and other nitroimidazole drugs, use of, in cancer therapy, 1406
- phase II study of, in the treatment of advanced colorectal carcinoma, 483
- MEV (methotrexate, cyclophosphamide [Endoxan], and vincristine)**, in the treatment of advanced non-Hodgkin's lymphomas: 5-year survey, 1193
- Mithramycin**, and calcitonin, symptomatic hypocalcemia following treatment for hypercalcemia due to malignancy, 1561
- Mitomycin C**
- and adriamycin: possible synergistic cardiotoxicity, 1005
- combined with constant-infusion 5-fluorouracil, methyl-CCNU, and vincristine in the treatment of advanced colorectal carcinoma, 1407
- combined with 5-fluorouracil, adriamycin, and cytosine arabinoside in the treatment of colorectal cancer, 1557
- combined with 5-fluorouracil, methyl-CCNU, and adriamycin in the treatment of advanced stomach cancer, 1287
- combined with vinblastine, phase II study of, in women with advanced breast cancer refractory to standard cytotoxic therapy, 2113
- phase II trial of fluorouracil with mitomycin C versus fluorouracil with methyl-CCNU in untreated colorectal cancer, 689
- plus cyclophosphamide and methotrexate, phase II study of, in drug-resistant colorectal cancer, 549
- plus 5-fluorouracil and adriamycin, phase II trial in advanced colorectal cancer, 563
- in the treatment of advanced adenocarcinoma and large cell lung cancer, 163
- MOCA (methotrexate, vincristine [Oncovin], cyclophosphamide, and adriamycin)**, given alone or with bacillus Calmette-Guérin or *Corynebacterium parvum*, in the treatment of unresectable lung cancer, 681
- MOPP (mechlorethamine, vincristine [Oncovin], prednisone, and procarbazine)**, failures, ABVD (adriamycin, bleomycin, vinblastine, and DTIC) treatment of, in Hodgkin's disease: a re-examination of goals of salvage therapy, 363
- Multiple myeloma** *see* Cancer, multiple myeloma
- Muramyl dipeptide**, and isoprinosine, levamisole, and SM1213, effects of, on lymphocyte and macrophage function in vitro, 1981
- Mycosis fungoides** *see* Cancer, lymphoma
- Myocardial biopsy**, use of, to monitor cardiotoxicity, 979, 1607

N

- Neoarsphenamine**, effect of actinomycin D and, on tumor control and skin tolerance in the rat, 713
- Neocarzinostatin**
- effects of systemic administration of, on human bladder cancer, 453

experimental and clinical studies on the formation of antibodies to, a new protein antibiotic, 2063
phase I and preliminary phase II study of, 2019
phase I study of, in children with cancer, 2105
phase I study of, in patients with acute leukemia, 1363
pulmonary reaction associated with, 1271

Neuroblastoma *see* Cancer, neuroblastoma

Neuromuscular toxicity *see* Adverse effects in man

Nitrosoureas, therapeutic potentiation of, using chlorpromazine and caffeine in the treatment of murine tumors, 2085

Nitrogen mustards, benzoic acid, as potential anticancer agents, synthesis of and testing against animal tumors, 2045

Nucleolar segregation, in skeletal muscle, cardiac muscle, and liver cells induced by adriamycin, 771

O

Osteogenic sarcoma *see* Tumor systems in animals and Cancer, osteosarcoma

Osteosarcoma (*see also* Cancer, osteosarcoma), Proceedings of the Osteosarcoma Study Group Meeting, 187-313

Ovarian cancer *see* Cancer, ovarian

3-Oxauracil, testing of, in mouse L1210 leukemia and 37 sarcoma, 2121

P

P388/ADR leukemia *see* Tumor systems in animals

PALA *see* N-Phosphonacetyl-L-aspartic acid

Peptichemio

clinical trial of, in solid tumors in children, 1015
in the treatment of advanced neuroblastoma, 811

Pharmacokinetics

of BCNU in man, 1305

comparative effects of citrovorum factor and carboxypeptidase G₁ on cerebrospinal fluid-methotrexate pharmacokinetics, 1549

pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice, 1025

pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer, 1

prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model, 1161

probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs, 1405

Phase I

of anguidine, 1497

and application in breast cancer: levamisole as an immunoadjuvant, 1693

of bacillus Calmette-Guérin in recurrent bladder papillomata, 551

of N⁶-benzyladenosine-5'-monophosphate, 1371

of BM 12.531, 1987

of *cis*-dichlorodiammineplatinum(II) by continuous iv infusion, 1553

of gallium nitrate, 1449

of high-dose methotrexate with modified citrovorum factor rescue, 397

of hycanthone in metastatic cancer, 1173

of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma, 1223

of maytansine, 429, 435

of maytansine using a 3-day schedule in advanced malignancies, 425

of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]- (*m*-AMSA), using a single-dose schedule, 1421

of neocarzinostatin, 2019

of neocarzinostatin in children with cancer, 2105

of neocarzinostatin in patients with acute leukemia, 1363

and oral absorption studies of, 401

of poly IC stabilized with poly-L-lysine, 1907

of pyrazofurin in the treatment of refractory acute myelogenous leukemia, 1569

of quelamycin, 1527

of vindesine in the treatment of advanced cancer, 1333

Phase II

of adriamycin and bleomycin in patients with multiple myeloma, 1367

of adriamycin and *cis*-dichlorodiammineplatinum(II) in squamous cell, ovarian, and testicular carcinomas, 1211

of 2,2'-anhydro-1- β -D-arabinofuranosyl-5-fluorocytosine in advanced colorectal cancer, 463

of Baker's antifol in advanced colorectal cancer, 553

of bleomycin in the treatment of bilharzial bladder cancer, 1109

of cyclophosphamide, vincristine, and methotrexate in advanced colorectal carcinoma, 1203

of dianhydrogalactitol in malignant glioma, 1199

of *cis*-dichlorodiammineplatinum(II) given by continuous iv infusion in the treatment of solid tumors, 1553
of *cis*-dichlorodiammineplatinum(II) in advanced breast cancer, 405

failure of moderate-dose prolonged-infusion methotrexate and citrovorum factor rescue in patients with previously treated metastatic neuroblastoma, 1097

of the failure of vincristine and bleomycin for previously treated children with metastatic neuroblastoma, 1201

of ftorafur with mitomycin C versus ftorafur with methyl-CCNU in untreated colorectal cancer, 689

of 5-fluorouracil, adriamycin, and mitomycin C in the treatment of advanced colorectal carcinoma, 563

of 5-fluorouracil plus melphalan in the treatment of colorectal cancer, 461

of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy, 173

of high-dose methotrexate and citrovorum factor rescue in patients with various tumors, 1295

of ICRF-159 in the treatment of non-Hodgkin's lymphoma, 465

- of ICRF-159 versus combination *cis*-dichlorodiammine-platinum(II) and DTIC in patients with disseminated malignant melanoma, 151
 - of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma, 1223
 - of maytansine in metastatic lung cancer, 1577
 - of maytansine in patients with advanced colorectal carcinoma, 1237
 - of melphalan in colorectal carcinoma, 1401
 - of methotrexate in carcinoma of the bilharzial bladder, 1075
 - of metronidazole in the treatment of advanced colorectal carcinoma, 483
 - of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy, 2113
 - of mitomycin C, cyclophosphamide, and methotrexate in drug-resistant colorectal carcinoma, 549
 - and oral absorption studies of cytembena, 401
 - of poly IC stabilized with poly-L-lysine, 1907
 - positive, of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea, 2095
 - preliminary, of neocarzinostatin, 2019
 - of pyrazofurin in the treatment of lung cancer, 451
 - of pyrazofurin in the treatment of metastatic sarcoma, 1573
 - of streptozotocin in the treatment of small cell anaplastic lung cancer, 477
 - of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy, 837
 - of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer, 1093
 - of vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and Hodgkin's disease: absence of cross-resistance with vincristine, 805
 - of vindesine in breast carcinoma, malignant melanoma, and other tumors, 1427
 - of VM-26 and hexamethylmelamine in the management of bilharzial bladder cancer, 993
 - of VM-26 in the treatment of metastatic malignant melanoma, 445
 - of Yoshi 864 in solid tumors, 389
 - N-Phosphonacetyl-L-aspartic acid (PALA)**, enzyme technique for measuring, in tissues, 1503
 - Phosphoramidate mustard**
 - comparative disposition of, and other cyclophosphamide metabolites, in the mouse using the *Salmonella*/mutagenesis assay, 1321
 - metabolite of cyclophosphamide, cross-linking of DNA in L1210 cells (LS2 and LM4 lines) and nuclei treated with, 23
 - Piperazinedione**, in advanced malignant melanoma, 1101
 - Platinum complexes** *see cis*-Dichlorodiammineplatinum(II)
 - P815 mastocytoma** *see* Tumor systems in animals
 - Podophyllotoxin**, analogs of, correlation of tubulin-binding and antitumor activities of, 1443
 - Poly IC**, phase I-II trials of, stabilized with poly-L-lysine, 1907
 - Polyribonucleosinic-polyribocytidylic acid** *see* Poly IC
 - Prednisone**
 - combined with cyclophosphamide and vincristine versus radiation therapy in the treatment of stage III-IV poorly differentiated lymphocytic lymphoma, 321
 - combined with cytosine arabinoside and vincristine in the treatment of adult acute lymphoblastic leukemia, 1389
 - Probenecid**, inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs, 1465
 - Procarbazine**
 - combined with cyclophosphamide, adriamycin, and methotrexate (CAMP) in the treatment of non-oat cell bronchogenic carcinoma, 1595
 - combined with cyclophosphamide, adriamycin, methotrexate, and radiation therapy in the treatment of stage III_{M0} non-oat cell lung cancer, 327
 - given with vincristine and CCNU, development of Hodgkin's disease in a patient being treated for gemistocytic astrocytoma, 177
 - Psychotropic drugs**, as potential antitumor agents: a selective screening study, 45
 - Pulmonary fibrosis**, interstitial *see* Adverse effects in man
 - Pyran copolymer** *see* Maleic anhydride-divinyl ether
 - Pyrazofurin**
 - phase I study of, in refractory acute myelogenous leukemia, 1569
 - phase II study of, in the treatment of lung cancer, 451
 - phase II study of, in the treatment of metastatic sarcoma, 1573
 - and triazinate, phase II study of, in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy, 837
- Q**
- Quelamycin**, phase I study of, 1527
- R**
- Radiation therapy**
 - central nervous system metastases in spite of prophylactic brain irradiation in oat cell carcinoma of the lung, 131
 - combined with cyclophosphamide, adriamycin, methotrexate, and procarbazine in the treatment of stage III_{M0} non-oat cell lung cancer, 327
 - effect of maleic anhydride-divinyl ether on the lymphocyte subpopulations of tumor-bearing, irradiated mice, 1831
 - effect of primary treatment modality on the metastatic pattern of mammary carcinoma, 1275
 - effects of combined immunotherapy with levamisole and bacillus Calmette-Guérin on immunocompetence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing, 1651

glycerol: a successful alternative to dexamethasone for patients receiving brain irradiation for metastatic disease, 1081
 postinduction whole-abdomen, combined with induction chemotherapy (cyclophosphamide, vincristine, and methotrexate) and prophylactic intrathecal methotrexate for Burkitt's lymphoma, 2031
 preliminary observations on the effect of glucan in combination with, in 4 murine tumors, 1867
 as preoperative therapy for osteosarcoma, 213
 primary, results of treating stage I and II breast cancer with, 985
 and thymosin, effect of, on immune modulation in head and neck and esophageal cancer patients, 1775
 total-body, versus cyclophosphamide, vincristine, and prednisone in the treatment of stage III-IV poorly differentiated lymphocytic lymphoma, 321
 whole-lung, with or without adriamycin in the treatment of osteosarcoma, 297

Radionuclide infusion, intra-arterial, a new technique to assess chemotherapy perfusion patterns, 699

Raynaud's phenomenon *see* Adverse effects in man

Renal cell cancer *see* Cancer, renal cell

Ridgway osteosarcoma *see* Tumor systems in animals

Rubidazone

cardiac toxicity of adriamycin-DNA complex and, evaluation by electrocardiogram and endomyocardial biopsy, 935
 clinical trial of, in advanced squamous cell carcinoma of the lung and adenocarcinoma of the large intestine, 1599
 clinical trial of, in solid tumors and malignant lymphomas, 1053

S

Salmonella/mutagenesis assay, used in the comparative disposition of phosphoramidate mustard and other cyclophosphamide metabolites in the mouse, 1321

Sarcylisin, combined with *cis*-dichlorodiammine-platinum(II) in the treatment of transplantable mouse tumors, 705

Sarcoma *see* Cancer, sarcoma

37 Sarcoma *see* Tumor systems in animals

180 Sarcoma *see* Tumor systems in animals

Scintigraphy, used for the early detection of hepatic metastasis, 1183

SM1213, and isoprinosine, levamisole, and muramyl dipeptide, effects of, on lymphocyte and macrophage function in vitro, 1981

Steroids

agents containing steroid nucleus and cytotoxic moiety considered for clinical use, 1241
 cytotoxic-linked estrogens, biochemical assays for the selection of, with potential therapeutic activity, 1255
 estrogen derivatives, comparative binding affinities of, 1243

problems in the development of cytotoxic moieties linked to hormones, 1267

steroid-nucleosides as potential chemotherapeutic agents, 1251

use of, as carriers of cytotoxic agents in breast cancer, 1259

Stomach cancer *see* Cancer, stomach

Streptozotocin

combined with methotrexate and bleomycin in the treatment of epidermoid carcinoma of the lung, 155
 failure of, in rare hormonally active malignancies, 847
 phase II trial of, in the treatment of small cell anaplastic lung cancer, 477
 in the treatment of advanced small cell lung cancer, 479

Surgery

and adjuvant bacillus Calmette-Guerin plus levamisole treatment of resectable lung cancer, preliminary results of, 1671
 amputation and adriamycin in primary osteosarcoma: 5-year report, 271
 effect of primary treatment modality in the metastatic pattern of mammary carcinoma, 1275
 en bloc resections for osteosarcoma, 225
 limited treatment in the management of early breast cancer, 983
 local en bloc resection for limb preservation after chemotherapy for osteosarcoma, 217
 as therapy for osteosarcoma, 213
 treatment of osteosarcoma, 205

Sister chromatid exchanges, in lymphocyte cultures of patients receiving chemotherapy for malignant disorders, 1413

T

Tamoxifen, retinopathy caused by, 315

Taxol, cytologic evidence that taxol acts as a mitotic spindle poison, 1219

Testicular cancer *see* Cancer, testicular

Tetrahydrouridine, pharmacokinetic considerations, in evaluating the effects of, on 5-azacytidine chemotherapy in L1210 leukemic mice, 1025

meso-Tetra(p-sulfophenyl)porphine, a potential tumor localizing agent, intracellular localization of, 511

180/TG Crocker tumor *see* Tumor systems in animals

Thiabendazole

and adriamycin versus adriamycin and chlorambucil in the treatment of extensive non-small cell carcinoma of the lung, 1215
 immunomodulation with, a review of immunologic properties and efficacy in combined modality cancer therapy, 1955

6-Thioguanine, and vinblastine in the treatment of advanced breast cancer, 1233

Thymoma *see* Cancer, thymoma

Thymosin

in cancer patients: in vitro effect and correlations with clinical response to thymosin immunotherapy, 1787

- characterization of peripheral blood null cells responsive to, 1757
- control of differentiation of thymocyte precursors in the bone marrow by thymic hormones, 1749
- experiences with, in primary immunodeficiency disease, 1779
- and irradiation, effect of, on immune modulation in head and neck and esophageal cancer patients, 1775
- overview of activity, 1731
- polypeptides, in vitro induction of Lyt surface markers on precursor cells incubated with, 1739
- suppressor cell activity in cancer patients: a possible role for thymic hormones, 1763
- thymosin-inducible lymphocytes in the peripheral blood of patients with malignant melanoma, 1769
- Tilorone**, and *Corynebacterium parvum*, *Brucella abortus* extract, bacillus Calmette-Guérin, glucan, and levamisole with or without cyclophosphamide, comparative effects of, on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model, 1919
- TNM classification**, an immunologic look: therapeutic implications and strategies, 1177
- α -Tocopherol**, effect of, on the cardiotoxicity of adriamycin in the rat, 1033
- Transfer factor**, immunotherapy with, versus high-dose methotrexate, vincristine, and adriamycin for nonmetastatic osteosarcoma, 289
- Transplantable osteogenic sarcoma** *see* Tumor systems in animals
- Triazene**, antimetastatic action of some derivatives of, against the Lewis lung carcinoma in mice, 721
- Triazinate** (*see also* Baker's antifol), and pyrazofurin, phase II study of, in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy, 837
- N-Trifluoroacetyl adriamycin-14-valerate**
- antitumor activity of, in mice, 105
- and adriamycin, comparative antineoplastic activity of, in mice, 111
- mouse antitumor and toxicity studies of, 119
- Tumor growth kinetics**, therapeutic differentials, and design of treatment schedules, 845, 846
- Tumor measurement**, simulation experiments of, in clinical trials, 2077
- Tumor systems in animals**
- 38 adenocarcinoma, response to hyperbaric hydrogen, 1077
- ADJ-PC5 plasmacytoma, restorative effect of levamisole on cell-mediated immune responses following chemotherapy with aniline mustard in mice bearing, 1627
- AKR leukemia
- lymphocytic, inhibition of tumor growth and enhancement of survival using glucan, 1857
- preliminary observations on the effect of glucan in combination with radiation and chemotherapy in, 1867
- transplantable, in mice, effect of, on hematopoietic stem cells, 737
- anaplastic 15091A mammary carcinoma, inhibition of tumor growth and enhancement of survival using glucan, 1857
- antitumor properties of 10-deaza-aminopterin in various, 1047
- BA1112 rhabdomyosarcoma, effect of actinomycin D and neoarsphenamine on tumor control and skin tolerance in rats with, 713
- B16 melanoma
- inhibition of tumor growth and enhancement of survival using glucan, 1857
- response to hyperbaric hydrogen, 1077
- therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of, 2085
- BW10232 adenocarcinoma, inhibition of tumor growth and enhancement of survival using glucan, 1857
- 16/C adenocarcinoma
- mouse mammary, biology and therapeutic response of, and its potential as a model for surgical adjuvant chemotherapy, 1471
- response to hyperbaric hydrogen, 1077
- CD8F₁ mammary adenocarcinoma, studies of growth, population kinetics, and host lethality of, 519
- 6C3HED lymphosarcoma, preliminary observations on the effect of glucan in combination with radiation and chemotherapy in, 1867
- chemotherapy of various transplantable mouse tumors with *cis*-dichlorodiammineplatinum(II) alone and in combination with sarcosyl, 705
- colon adenocarcinoma (CX-2) xenografts, inactivity of DL-amygdalin against, 576
- colon adenocarcinoma (MAC-15A), transplantable, chemotherapy of, in mice: development and characterization of an ascitic line, 85
- EMT-6 mouse tumors
- enhancement by hyperthermia of the effect of BCNU against, 439
- preliminary observations on the effect of glucan in combination with radiation and chemotherapy in, 1867
- Gross leukemia
- antitumor activity of N-trifluoroacetyl adriamycin-14-valerate in, 105
- synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4-epiadriamycin in, 375
- human bladder tumors, activity of human fibroblast interferon in, 1899
- human breast carcinoma (MX-1) xenografts, inactivity of DL-amygdalin against, 576
- 180 Japan sarcoma, regression of, after treatment with substituted indoloquinolones, 1575
- Jensen sarcoma, benzoic acid nitrogen mustards tested in animals with, 2045
- KHT fibrosarcoma, preliminary observations on the effect of glucan in combination with radiation and chemotherapy in, 1867
- L1210 Cr leukemia, preliminary characterization in mice of the effect of isoprinosine on the immune system, 1975
- Lewis lung carcinoma
- antimetastatic action of some triazene derivatives against, in mice, 721

- antitumor evaluation of maleic anhydride-divinyl ether linked with methotrexate, 1837
- comparative antineoplastic activity of adriamycin and *N*-trifluoroacetyladiamycin-14-valerate in, 111
- distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice bearing, 791
- improved therapeutic index of bleomycin when administered by continuous infusion in mice with, 2011
- relationship of molecular weight to antiviral and antitumor activities and toxic effects of maleic anhydride-divinyl ether polyanions, 1797
- response to hyperbaric hydrogen, 1077
- therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of, 2085
- L1210 Ha leukemia, preliminary characterization in mice of the effect of isoprinosine on the immune system, 1975
- L1210 leukemia
- antitumor activity of *N*-trifluoroacetyladiamycin-14-valerate in, 105
 - antitumor and toxicity studies using *N*-trifluoroacetyladiamycin-14-valerate, 119
 - antitumor evaluation of maleic anhydride-divinyl ether linked with methotrexate, 1837
 - benzoic acid nitrogen mustards tested in animals with, 2045
 - chronochemotherapy with cytosine arabinoside or cyclophosphamide in mice with, 1337
 - comparative adjuvant effects of levamisole and *Brucella abortus* in, 1943
 - comparative antineoplastic activity of adriamycin and *N*-trifluoroacetyladiamycin-14-valerate in, 111
 - influence of continuous infusion of cytosine arabinoside on sequencing with daunorubicin in, 547
 - lack of therapeutic synergism between vincristine and methotrexate in, 997
 - pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in, 1025
 - response to hyperbaric hydrogen, 1077
 - synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4'-epiadriamycin in, 375
 - testing of 3-oxauracil in, 2121
 - therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of, 2085
 - therapy and toxicology studies in mice with β -2'-deoxythioguanosine, 135
- LSTRA lymphoma
- comparative antineoplastic activity of adriamycin and *N*-trifluoroacetyladiamycin-14-valerate in, 111
 - response of, to combined BCNU-maleic anhydride-divinyl ether (MVE) adjuvant therapy and correlation with macrophage activation by MVE in the in vitro growth inhibition assay, 1807
- 109 Madison lung carcinoma
- comparative adjuvant effects of levamisole and *Brucella abortus* in, 1943
 - effect of maleic anhydride-divinyl ether on the lymphocyte subpopulations of irradiated mice with, 1831
- mammary carcinoma
- distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice bearing, 791
 - spontaneous, comparative effects of *Corynebacterium parvum*, *Brucella abortus* extract, bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in, 1919
 - synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4'-epiadriamycin in, 375
 - therapeutic implications of cell kinetic changes after cyclophosphamide treatment of "spontaneous" and "transplacental (13762)," 727
- Meth A sarcoma, immunomodulating effects of BM 12.531 in mice with, 1987
- osteogenic sarcoma
- activation of reticuloendothelial system macrophages and enhancement of host resistance to, by an extract of *Brucella abortus*, 1931
 - antitumor activity of interferon against, in vitro and in vivo, 1881
- P388/ADR leukemia, antitumor and toxicity studies using *N*-trifluoroacetyladiamycin-14-valerate, 119
- P388 leukemia
- antitumor activity of fungal metabolites: verrucarins β -9,10-epoxides, 1585
 - antitumor activity of *N*-trifluoroacetyladiamycin-14-valerate in, 105
 - comparative antitumor activity of actinomycin analogs in mice bearing, 779
 - in vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of, 1535
 - synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4'-epiadriamycin in, 375
- P815 mastocytoma, relationship of molecular weight to antiviral and antitumor activities and toxic effects of maleic anhydride-divinyl ether polyanions, 1797
- Ridgway osteosarcoma
- antitumor and toxicity studies using *N*-trifluoroacetyladiamycin-14-valerate, 119
 - comparative antitumor activity of actinomycin analogs in mice bearing, 779
 - response to hyperbaric hydrogen, 1077
- 37 sarcoma, testing of 3-oxauracil in, 2121
- 180 sarcoma
- antitumor activity of *N*-trifluoroacetyladiamycin-14-valerate in, 105
 - synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4'-epiadriamycin in, 375
- 180/TG Crocker tumor, isoprinosine used to increase the antitumor action of interferon in mice with, 1971
- transplantable osteogenic sarcoma, activation of reticuloendothelial system macrophages and enhancement of host resistance to, by an extract of *Brucella abortus*, 1931
- VX2 liver carcinoma, intra-arterial chemotherapy with concomitant use of vasoconstrictors for, 145

Walker 256 carcinosarcoma, benzoic acid nitrogen mustards tested in animals with, 2045

U

Uterine cancer *see* Cancer, uterine

V

Vasoconstrictors, intra-arterial chemotherapy with concomitant use of, for liver cancer in rabbits, 145

Verrucaric acid, antitumor activity of, 1585

Vinblastine

and adriamycin, hydroxyurea, and medroxyprogesterone acetate, chemohormonal therapy for metastatic renal cell carcinoma, 1379

combined with adriamycin, bleomycin, and DTIC and used to treat MOPP failures with Hodgkin's disease: re-examination of goals of salvage therapy, 363

combined with bleomycin, Raynaud's phenomenon as a side effect of treatment for testicular cancer, 569

combined with *cis*-dichlorodiammineplatinum(II) and bleomycin in the treatment of testicular cancer: variables for predicting serious toxicity (vinblastine dose, performance status, and prior therapeutic experience), 1455

combined with mitomycin C, phase II study of, in women with advanced breast cancer refractory to standard cytotoxic therapy, 2113

plus methyl-CCNU and medroxyprogesterone in the treatment of advanced renal cell cancer: phase II study, 1093

and 6-thioguanine in the treatment of advanced breast cancer, 1233

with bleomycin, compared with vincristine, bleomycin, and actinomycin D in the treatment of disseminated germinal tumors of the testis, 129

Vincristine

and adriamycin and cyclophosphamide, unusual neuromuscular toxicity after treatment of bone sarcomas, 1408

ataxia and athetosis as side effects of the treatment of non-Hodgkin's lymphoma, 561

and bleomycin, phase II study of the failure of, for previously treated children with metastatic neuroblastoma, 1201

combined with constant-infusion 5-fluorouracil, methyl-CCNU, and mitomycin C in the treatment of advanced colorectal carcinoma, 1407

combined with cyclophosphamide and methotrexate, phase II trial in the treatment of advanced colorectal carcinoma, 1203

combined with cyclophosphamide and methotrexate, prophylactic intrathecal methotrexate, and postinduction whole-abdomen radiotherapy for Burkitt's lymphoma, 2031

combined with cyclophosphamide and prednisone ver-

sus radiation therapy in the treatment of stage III-IV poorly differentiated lymphocytic lymphoma, 321

combined with cytosine arabinoside and prednisone in the treatment of adult acute lymphoblastic leukemia, 1389

combined with methotrexate, cyclophosphamide, and adriamycin (MOCA) with or without bacillus Calmette-Guérin or *Corynebacterium parvum* in the treatment of unresectable lung cancer, 681

combined with methotrexate and cyclophosphamide (MEV) in the treatment of advanced non-Hodgkin's lymphomas: 5-year survey, 1193

comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of cervical cancer, 1435

and high-dose methotrexate, citrovorum factor rescue, adriamycin, and cyclophosphamide in the treatment of osteosarcoma, 283

given with CCNU and procarbazine, development of Hodgkin's disease in a patient being treated for gemistocytic astrocytoma, 177

and methotrexate, lack of synergism between, in L1210 murine leukemia in vivo, 997

as part of the multidrug adjuvant chemotherapy (COMPADRI-I, COMPADRI-II, and COMPADRI-III) for osteosarcoma, 265

phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and Hodgkin's disease: absence of cross-resistance with, 805

plus adriamycin, cyclophosphamide, *cis*-dichlorodiammineplatinum(II), and bacillus Calmette-Guérin or *Corynebacterium parvum* in the treatment of stage III lung cancer, 505

plus high-dose methotrexate and adriamycin versus transfer factor immunotherapy in the treatment of nonmetastatic osteosarcoma, 289

used with methotrexate and citrovorum factor rescue, with or without adriamycin, as preoperative therapy for osteosarcoma, 217

with bleomycin and actinomycin D, compared with vinblastine and bleomycin in the treatment of disseminated germinal tumors of the testis, 129

Vindesine

phase I trial in the treatment of advanced cancer, 1333

phase II clinical trial with, for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and Hodgkin's disease: absence of cross-resistance with vincristine, 805

phase II study of, in the treatment of breast carcinoma, malignant melanoma, and other tumors, 1427

VM-26

and hexamethylmelamine, a phase II trial in the chemotherapeutic management of bilharzial bladder cancer, 993

phase II trial of, in the treatment of metastatic malignant melanoma, 445

and VP-16-213, kinetics of cytotoxicity of, on L1210 leukemia and hematopoietic stem cells, 1313

VP-16-213

evaluation of, in malignant lymphoma and melanoma, 801

in the treatment of advanced squamous cell carcinoma and adenocarcinoma of the lung, 843

in the treatment of small cell lung cancer: a randomized trial using 3 dosage schedules, 473

and VM-26, kinetics of cytotoxicity of, on L1210 leukemia and hematopoietic stem cells, 1313

VX2 liver carcinoma *see* Tumor systems in animals

W

Walker 256 carcinosarcoma *see* Tumor systems in animals

X

Xenografts, inactivity of DL-amygdalin against human breast and colon tumor xenografts in athymic (nude) mice, 576

Y

Yoshi 864 (1-propanol, 3,3'-iminodi-, dimethanesulfonate [ester], hydrochloride), phase II study of, in solid tumors, 389

Author Index

A

Abbott BJ, 45
Abeloff MD, 413
Abelson HT, 1549, 1999
Ablin AR, 1097
Adams GE, 1406
Adamson RH, 31, 1837
Ahmann DL, 151, 837
Ahmed A, 1739
Aisner J, 673, 1229
Aitken SC, 1281
Al-Sarraf M, 801, 1101
Albers JW, 483
Alberts DS, 143
Alexander JA, 755
Allegra JC, 1281
Altman SJ, 389
Amery WK, 1677
Amin VC, 887
Ammann AJ, 1775
Anderson R, 1671
Anderson T, 1075
Appelbaum FR, 247
Aravantos D, 1387
Arcamone F, 375
Armitage JO, 1389
Arseneault J, 159
Astaldi A, 1779
Astaldi GCB, 1779
Aur RJA, 2105
Austen JD, 511
Autenrieth D, 1251
Azarnoff DL, 13

B

Baccarani M, 1193
Bagley C, 1671
Bailar JC, 1367
Bailey C, 907
Bains M, 1041
Bakemeier RF, 1367
Baker LH, 19, 163, 237, 455, 689, 1223, 1599
Balcerzak SP, 401, 881, 893
Banks HH, 295
Bannister SJ, 1359
Bara A, 823
Barbieri B, 791
Barker AD, 576
Barker M, 747

Barkes P, 1375
Barlock A, 1281
Barlow JJ, 559
Barnes DW, 1797
Bassett WB, 1405
Bateman JR, 465, 1161
Bedikian AY, 1081, 1449, 1603
Begg CB, 159
Bellet RE, 445, 2095
Belpomme D, 805
Belt R, 1359
Bender RA, 233, 997, 1421
Benjamin RS, 237, 931, 935, 1081, 1449, 1513, 1553
Bennett JM, 1367
Berd D, 445, 2095
Berman R, 457
Bernardi L, 375
Bernath AM, 155, 477, 1521
Bernstein I, 1671
Bernstein ID, 1201
Bertino JR, 1009
Besarab A, 1561
Bicker U, 1987
Billingham ME, 857, 865, 873, 935, 963, 1607
Billings A, 327
Bird GG, 457
Bisel HF, 151
Bitran JD, 327, 567
Bjornsson S, 505
Blanc AP, 1110
Blaschke T, 1465
Blessing JA, 833, 1435
Bleyer WA, 1097
Block JB, 1295
Blum RH, 435, 923, 2019
Blumenschein GR, 405, 1005, 1565, 1685
Bodenham DC, 1769
Bodey GP, 425, 493, 1059, 1081, 1089, 1139, 1173, 1449, 1497, 1553, 1603
Bodey GP, Sr, 405
Boldrey EB, 2071
Bolis G, 2117
Bonadonna G, 279
Bonnard GD, 1893
Bono VH, Jr, 178
Bonomi PD, 1211, 1595
Boronow RC, 833, 1435
Braine HG, 413
Braun D, Jr, 1693
Braunschweiger PG, 727
Briscoe KE, 2027
Bristow MR, 857, 865, 873, 1607
Britell JC, 1207

Broder LE, 155
 Brogini M, 791
 Browder WI, 1857
 Brown BW, Jr, 1455
 Brown O, 341
 Brownlee RW, 19
 Bruckner H, 159, 555, 1021
 Brugarolas A, 1527
 Bruley-Rosset M, 1613, 1641
 Brunner KW, 473
 Brunton GF, 845
 Buesa JM, 1527
 Buffett RF, 1899
 Bukowski RM, 570
 Bunch GA, 457
 Bungay PM, 1
 Bunn PA, Jr, 155, 479, 1287
 Burchenal JH, 463
 Burgess MA, 425, 1449, 1497, 1603
 Burke PJ, 413
 Burns CP, 1389
 Buroker TR, 553, 689, 1599
 Busch H, 771
 Butler TP, 169
 Buzdar AU, 405, 1005, 1565, 1685
 Byrom NA, 1769

C

Cabanillas F, 425
 Caceres E, 297
 Cain BF, 2035
 Cairns J, 1075
 Cairo M, 111
 Calman KC, 489
 Campbell A, 489
 Campbell MA, 1769
 Canellos GP, 321, 2019
 Cangir A, 167
 Caoili E, 19
 Carbone PP, 1093, 1367
 Carcassonne Y, 1110
 Caro JF, 1561
 Carpentieri U, 561
 Carrano CJ, 511
 Carter SK, 199
 Carter WA, 1897, 1899
 Carter WH, Jr, 333
 Casazza AM, 105, 375
 Cashdollar MR, 477, 1521
 Catalano RB, 445, 2095
 Catane H, 505
 Catane R, 178, 1371
 Cavalli F, 473, 2125
 Cecil JW, 801
 Cerna I, 1065
 Cerutti I, 1971
 Chabner BA, 321, 429
 Chahinian AP, 1108

Chan KK, 381, 1161
 Chany C, 1971
 Charrois R, 551
 Chatterji DC, 487
 Chernicoff DP, 570
 Chevlen E, 1109
 Childs DS, 483
 Chirigos MA, 1611, 1817, 1831, 1837, 1845, 1889, 1937, 1943, 1949
 Chitnis MP, 1535
 Chou C, 887
 Chou SC, 1637
 Chou T-H, 147
 Chretien PB, 1787
 Christakis J, 893
 Cifuentes de Castro L, 85
 Clamon GH, 363
 Clausen OPF, 351
 Cline MJ, 681
 Cohen CJ, 555, 1021
 Cohen JL, 381, 1161
 Cohen ME, 819
 Cohen MH, 155, 479, 1287, 1787
 Cohen S, 169
 Cohn I, Jr, 2077
 Collins JM, 1823, 2011
 Colman M, 327
 Colombo T, 791
 Coltman CA, Jr, 129, 801, 1215
 Come S, 1509
 Comelli A, 811
 Comes R, 823
 Comis RL, 163, 2019
 Cone L, 1295
 Congleton G, 45
 Connelly K, 1065
 Cooksey JA, 567
 Cooney DA, 1503
 Cooper MR, 1085, 1233
 Copeland EW, 1139
 Corbett TH, 519, 1077, 1471
 Corder MP, 363, 465
 Correa J, 553
 Cortes EP, 271, 887
 Coulonval L, 551
 Coulter D, 1313
 Cozzutto C, 811
 Crafts DC, 177
 Crane JL, Jr, 1881, 1931
 Creagan ET, 178, 843, 1207, 1404, 1577
 Creasman WT, 833
 Creech R, 159
 Critchfield CF, 91
 Croke ST, 163
 Cruze D, 915
 Cubillan J, 1503
 Currie VE, 451, 1333
 Curtis CR, 1585
 Cvitkovic E, 693, 1041

D

Dagna-Bricarelli F, 1779
 Dahlin DC, 189
 Daniels JR, 857, 865, 873, 1455, 1607
 Daskal Y, 771
 Davignon JP, 45, 99
 Davigny M, 1641
 Davis S, 1557
 De Bernardi B, 811
 De Luca L, 805
 de Vassal F, 805, 1613
 Dean AJ, 1769
 Dean JH, 1627, 1807
 Dedrick RL, 1
 Deen DF, 747, 2055
 Deisseroth AB, 2031
 deKernion J, 1709
 Denefrio JM, 173, 2113
 Denine EP, 533
 Deppe G, 555, 1021
 Desai SA, 1203
 Desser RK, 327, 567
 DeGraw JI, 1047
 DeMattia M, 689
 DeMeester TR, 327, 567
 DeVita VT, Jr, 1, 321
 DeWys WD, 1203
 Di Luzio NR, 1857
 Di Marco A, 105, 375
 Dicke K, 1763
 Didolkar MS, 1329
 D'Incalci M, 2117
 Dindogru A, 689
 Dingell JV, 31
 Dionne L, 551
 DiBenedetto J, Jr, 1401
 Djeu JY, 1893
 Do HMT, 1281
 Dobre V, 2045
 Dolen JG, 1899
 Dollinger M, 1295
 Donaldson J, 439
 Donaldson MH, 907
 Donaldson SS, 1489
 Donelli MG, 791
 Dorey FJ, 681
 Dorick DM, 1047
 D'Orsi CJ, 699, 1271
 Dosik G, 1513
 Double JA, 85
 Douglass HO, Jr, 239
 Douville Y, 551
 Driscoll JS, 45
 Dudeck L, 45
 Dudrick SJ, 1139
 Dykes DJ, 2085
 Dymont PG, 265, 2109

E

Eagan RT, 843, 1207, 1577
 Earhart RH, 1105
 East DR, 2113
 Eddy JL, 1287
 Edelstein M, 547
 Edmonson JH, 151, 289, 837
 Egan EM, 1509
 Eilber FR, 213, 1295
 Einhorn LH, 1351
 El Dareer SM, 75
 El-Morsi B, 993
 El-Sebai IT, 993
 Elias EG, 1106
 Elson J, 963
 Embrey WM, 1535
 Ensminger WD, 699, 1509, 1549
 Espana P, 1199
 Esterhay RJ, Jr, 1229
 Etcubanas E, 283
 Ettinger DS, 413
 Evans AE, 1201
 Evans JT, 1371, 1401
 Evans R, 327
 Evans WE, 1381
 Ewy GA, 915
 Ezdinli E, 1367

F

Feingold DS, 1915, 1931, 1943
 Fellows KE, 217
 Ferrans VJ, 955
 Feyns V, 2045
 Fiacchini M, 1193
 Fife WP, 1077
 Finklestein JZ, 1097, 1201
 Fischer GW, 1637
 Fischer JJ, 713
 Fisher B, 1919
 Fisher WB, 91
 Flannery EP, 465
 Fletcher WS, 389
 Florentin I, 1613, 1641
 Folkers K, 887
 Folland ED, 941
 Fontanillas L, 279
 Fossati Bellani F, 279
 Foster JL, 1270
 Fountain KS, 178
 Fowler WC, Jr, 1435
 Fox P, 1145
 Fraile RJ, 163, 1223, 1599
 Franchi G, 375
 Franks CR, 1379
 Frederiksen PL, 449

Freeman AI, 239, 819
 Frei E III, 259, 923
 Freireich EJ, 425, 493, 1081, 1139, 1449, 1497
 Frezza R, 1193
 Friedman M, 199
 Friedman MJ, 915
 Frytak S, 151, 483, 843, 1207, 1271, 1404, 1577
 Fuchs DA, 1219
 Fulkerson PK, 881
 Fusner JE, 1465
 Fyfe MJ, 341

G

Gad-el-Mawla NM, 993, 1075, 1109
 Gaines J, 915
 Gajjar PD, 457
 Gallelli JF, 487
 Garattini S, 791, 2117
 Gasparini M, 279
 Gastaut JA, 1110
 Gaudio L, 1025
 Gause GF, 1227
 Gebhardt M, 1919
 Geelhoed GW, 1065
 Gehan EA, 265
 Gennari L, 279
 George S, 251
 Giardino P, 375
 Gilchrist GS, 289
 Giles GR, 457
 Gingrich RD, 1389
 Ginsberg S, 163
 Giraldi T, 721
 Gisolfi AL, 345
 Giuliani F, 375
 Glasgow LA, 1881, 1931
 Glasky AJ, 1963
 Glaubiger DL, 1421, 1465, 2031
 Glennon JA, 1561
 Glidewell O, 271
 Gobbi M, 1193
 Goepfert H, 167
 Golbey RB, 451, 1041
 Goldin A, 307
 Goldstein AL, 1731, 1739, 1749
 Golomb HM, 327, 567
 Gonzales F, 135
 Gonzalez RL, 1703
 Gonzalez-Vitale JC, 693
 Gordon LF, 1489
 Gormley P, 1421
 Gosalvez M, 1527
 Gottdiener JS, 949
 Gottlieb JA, 237, 931
 Gouveia J, 805
 Gralla RJ, 451, 1573
 Gram TE, 2011
 Grant T, 213
 Graw RG, Jr, 247

Gray MM, 489
 Greco FA, 901, 1407
 Green AA, 251
 Green D, 1145
 Green DM, 829, 1517
 Green L, 1281
 Greenspan EM, 555, 1021
 Gregory EB, 1535
 Griem M, 327
 Griffin TW, 1271, 2019
 Griswold DP, Jr, 519, 1471
 Groppe CW, Jr, 801, 1101
 Grose WE, 1173
 Gross JF, 1161
 Groth C, 689
 Grunberg E, 1575
 Gupta M, 887
 Gusberg SB, 555
 Gutterman JU, 1059, 1081, 1685

H

Haas CD, 129, 1215
 Hadden JW, 1981
 Hahn D, 1591
 Hahn GM, 1489
 Hahn RG, 159, 1093, 1404
 Hall R, 457
 Hall SW, 180, 425, 1449, 1553
 Haller DG, 563
 Hamilton GW, 941, 945
 Hamilton R, 1581
 Hammond GD, 1097, 1201
 Hamsa R, 1075, 1109
 Hamza MR, 993
 Handelsman H, 187
 Hansen HH, 849, 1053
 Hansen M, 849
 Harper E, 1413
 Harris JR, 985
 Harrison SD, Jr, 533
 Hartmann JR, 1097
 Harvey HA, 1581
 Haskell CM, 573, 681
 Haut A, 1101
 Hayashi M, 743
 Hayat M, 805
 Hayes DM, 693
 Hayward JL, 983
 Hedley DW, 1427
 Heilbrun LH, 1215
 Heilbrun LK, 1081
 Hellman S, 985, 1275
 Henderson E, 505
 Henderson IC, 923
 Hensley MF, 167
 Herberman RB, 1893
 Herbst KD, 91
 Herman PJ, 1271
 Hersh EM, 1059, 1685, 1763

Hertz R, 2101
 Heuson J-C, 1255, 1267
 Hewlett JS, 469
 Higby DJ, 239, 505, 559
 Higgins G, 135
 Hignite CE, 13
 Hilal EY, 1663
 Hill DL, 75, 1153
 Hill LD, 1671
 Hillcoat BL, 23
 Himmelstein KJ, 1161, 1359
 Hirshaut Y, 1663, 1693
 Hirst M, 119
 Hittle R, 1201
 Hobbs JR, 1769
 Hoffman WF, 1305, 2071
 Hokama Y, 1637
 Holden HT, 1893
 Holland JF, 271, 555, 1021, 1108
 Holyoke ED, 1329, 1899
 Hoogstraten B, 19, 455, 841
 Hopfan S, 1041
 Horoszewicz JS, 1897, 1899
 Hortobagyi GN, 405, 1005, 1685
 Horton J, 159, 1093
 Hoshino T, 747, 2055
 Houchens DP, 576
 Houghton PJ, 721
 Howard J, 1041
 Howarth C, 2105
 Howser D, 1421
 Hreshchyshyn MM, 1435
 Hu MSJ, 1455
 Hu SK, 1731
 Hubbard SM, 1375
 Huff KK, 1281
 Hulsinga E, 1251
 Hutchinson RJ, 907
 Hutchison DJ, 345

I

Ignoffo R, 143
 Ihde DC, 155, 479, 1287
 Ihle JN, 1749
 Ikegami K, 453
 Ing R, 45
 Ingle JN, 837, 843, 1207, 1577
 Inokuchi K, 145
 Inoue K, 743
 Isacoff WH, 1295
 Israel L, 1177
 Israel M, 119
 Issell BF, 1059, 1089, 1139
 Ito M, 1899
 Ivey T, 1671
 Ivins JC, 205, 289
 Iwaki A, 145

J

Jacobs SA, 397
 Jaffe N, 217, 259, 923
 Jaffrey IS, 573
 Jarvis BB, 1585
 Jasmin CI, 805
 Jayaram HN, 1503
 Job L, 1899
 Joergensen ST, 449
 Johnson BL, 429
 Johnson GJ, 574
 Johnson L, 1671
 Johnson RE, 321
 Johnson RK, 1219, 1535
 Jones SE, 19, 129, 841, 915
 Jungi F, 473

K

Kabakow B, 555, 1021
 Kahlert T, 435
 Kaiser-Kupfer MI, 315
 Kalish R, 1313
 Kan G, 1251
 Kanda K, 743
 Kane RC, 477, 1521
 Kaplan AM, 1823
 Kaplan J, 1757
 Kaplan WD, 699
 Karakousis CP, 1329, 1899
 Karlowicz MG, 1503
 Karp JE, 413
 Kaskarelis D, 1387
 Katakhar SB, 1379
 Kater L, 1779
 Katzenellenbogen JA, 1243
 Kaufman JH, 1371
 Kaufman JJ, 1709
 Kawase I, 139
 Keating MJ, 493
 Kedar A, 819
 Kehoe R, 963
 Keleti G, 1915
 Kelleher JK, 1443
 Kellick MG, 345
 Kelly CJ, 1025
 Kelsen DP, 1041
 Kemeny N, 463
 Kenady DE, 1787
 Kennedy BJ, 2027
 Kennedy JW, 941, 945
 Kent HC, 2031
 Kern ER, 1881, 1931
 Kerns AL, 1587
 Kessel D, 147
 Kesselheim H, 1693
 Keys L, 1807
 Khafagy M, 993

Khan T, 1106
 Khandekar JD, 1397
 Khilani P, 147
 Kibrité A, 551
 Kiger N, 1613, 1641
 Klahr C, 461, 549
 Klein P, 1295
 Kleinman D, 881
 Kleinman LM, 99
 Klemperer M, 1201
 Klubes P, 1065
 Knebel KD, 747, 2055
 Knecht M, 2101
 Kobayashi M, 145
 Kobayashi T, 139
 Kodlin D, 2077
 Koeffler HP, 573
 Kondo H, 743
 Konovalova AL, 705
 Koons LS, 445
 Koshiba Y, 743
 Krakoff IH, 1333
 Krikorian JG, 1455
 Krishan A, 829
 Krutchik AN, 1005, 1565
 Kuberka N, 505
 Kumar APM, 251
 Kvols LK, 151, 837, 843

L

Lacave AJ, 1527
 Lambert B, 1413
 Lamedica G, 811
 Laster WR, Jr, 779, 1337, 2085
 Laszlo J, 341
 Lau ME, 849
 Lauria F, 1193
 Lawrence B, 1581
 Leclercq G, 1255
 Lee ET, 931
 Lee L, 341
 Lee W, 1355
 Lee Y-TN, 1161, 1183
 Legha SS, 180, 1005, 1173
 Lehane D, 129
 Leier CV, 881
 Leikin S, 1097, 1201
 Lele SB, 559
 Lemkin S, 1295
 Lenaz GR, 499
 Lengel CR, 1831, 1949
 Leong SS, 1899
 Lerner HJ, 1135
 Levandowski R, 963
 Levene MB, 985
 Levi JA, 1229
 Levin DC, 699
 Levin VA, 177, 1305, 2071

Levine AS, 247, 429, 1421, 1907, 2031
 Levitt M, 131, 1367
 Levy HB, 1907
 Levy J, 1715
 Lewis DD, 1627
 Lewis RP, 881, 893
 Lincoln B, 1709
 Lindblad A, 1413
 Lippman ME, 315, 1259, 1267, 1281
 Lipscomb DL, 1587
 Lipson SD, 1787
 Lipton A, 1581
 Livingston RB, 1215, 1497, 1603
 Llanderal AP, 1527
 Lo PS, 713
 Lockhart LH, 561
 Lokich JJ, 2019
 Lomax N, 45
 Long HJ, 911
 Lopez R, 1329
 Louie AC, 178, 233, 301
 Lovett EJ III, 1955
 Low TLK, 1731
 Lowitz BB, 681
 Luce JK, 2009
 Ludlum DB, 529
 Luetzeler J, 1817
 Luna MA, 1005
 Lundy J, 1955

M

Macdonald JS, 563
 Machover D, 805
 Madden RE, 389
 Maeda H, 453, 2063
 Magill GB, 1573
 Magrath IT, 247, 2031
 Makuch R, 1037, 1787
 Malhotra A, 457
 Malspeis L, 401, 893
 Mandel EM, 1108
 Mandel HG, 1065
 Mangioni C, 2117
 Mansell PW, 1587
 Mansell PWA, 1873
 Mansour MA, 993
 Mantovani A, 111
 Marco MG, 1527
 Marcove RC, 225
 Marlis AS, 1161
 Marsh J, 1093
 Marshall GD, Jr, 1731
 Martin DS, 1791
 Martin M, 551
 Martoni A, 499
 Mason BH, 2035
 Mason GR, 1106
 Mason JW, 857, 865, 873, 935, 1607
 Massicot JG, 1845

Massimo L, 811
 Mastrangelo MJ, 445, 2095
 Mathe G, 805, 1613, 1641
 Matsumoto T, 2063
 Maurus R, 1015
 Mavligit GM, 1763
 Maximova TS, 1227
 Maybee D, 1637
 McConnell S, 511
 McConnell WR, 1153
 McCoy JL, 1627
 McCredie KB, 493
 McDonald B, 1223
 McDonald CJ, 1009
 McElwain TJ, 1427
 McEwan RN, 1749
 McGuire WP, 855
 McKeever WP, 1397
 McKelvey EM, 469
 McLaren JR, 1651
 McMahan RT, 843
 McNamee R, 1857
 McPherson TA, 571
 Mehta BM, 345
 Meikle A, 131
 Melnick NR, 45
 Mercurio T, 1581
 Merski J, 771
 Metter GE, 389
 Mhatre RM, 1145
 Miale T, 265
 Mielants M, 1721
 Mikè V, 1663
 Mimnaugh EG, 2011
 Mindell ER, 239
 Minna JD, 155, 479, 1287, 1787
 Minow RA, 931
 Mintz U, 567
 Mircheva JJ, 2121
 Missel JL, 805
 Mittelman A, 1371, 1401
 Moayeri H, 1401
 Moccio DM, 1047
 Moertel CG, 483, 1237
 Momparder L, 135
 Momparder RL, 135
 Moon TE, 129, 237
 Moore RP, 1355
 Morahan PS, 1797, 1823
 Moran M, 297
 Morasca L, 2117
 Morgan JE, 439
 Mori PG, 811
 Morimoto T, 743
 Morrison F, 19
 Morton DL, 213
 Moulder JE, 713
 Mouridsen HT, 449, 1053
 Muggia FM, 178, 187, 233, 301, 993, 1241, 1267
 Muhm JR, 1404
 Multhauf PM, 389

Munger D, 409
 Munson AE, 1797
 Murphy WK, 1497, 1553
 Murray N, 131
 Muss HB, 1085, 1233
 Musset M, 805
 Mustea I, 823
 Myers CE, 1, 979

N

Nagasue N, 145
 Nakeff A, 737
 Nanni P, 499
 Narahara KA, 945
 Nealon TF, 389
 Necheles TF, 295
 Neidhart JA, 401
 Nichols AP, 997
 Nichols WC, 837
 Niculescu-Duvăz I, 2045
 Niitani H, 139
 Nime FA, 1371
 Nirenberg A, 345
 Nishiwaki Y, 139
 Nisi C, 721
 Nissen NI, 1053
 Nitschke R, 2109
 Nomura K, 747, 2055
 Nomura Y, 743
 Northing JW, 1627
 Norton L, 846, 997
 Nugent JL, 1287

O

O'Brien J, 1637
 O'Bryan RM, 237, 455, 841, 1599
 O'Connell MJ, 837, 1237
 Ochs JJ, 239
 Oettgen HF, 1663, 1693
 Ogata J, 453, 2063
 Oh WH, 295
 Ohnuma T, 2027
 Okazaki K, 743
 Oken MM, 574, 1367
 Olchovatova OL, 1227
 Oldham RK, 1407
 Olkowski ZL, 1651
 Olson HM, 893
 Olsson L, 1613
 Omura GA, 833
 Orbach-Arbouys S, 1613
 Ortaldo JR, 1893
 Ostrow S, 1591
 Otten J, 1015
 Ovejera AA, 576

P

Pacciarini MA, 791
 Pachon N, 1527
 Padarathsingh ML, 1627, 1807
 Padilla F, 553, 1101
 Pairolero P, 1404
 Pajak TF, 465
 Panasci LC, 1145
 Pannuti F, 499
 Papamatheakis JD, 1845
 Papavasiliou C, 1387
 Pappas J, 1387
 Park YK, 1557
 Parker LM, 119
 Pasmantier MW, 2027
 Patelli B, 375
 Paterson AHG, 571, 1269
 Patt YZ, 1763
 Patton TF, 409, 1359
 Pavlidis NA, 1817, 1889, 1937, 1943
 Pazmiño NH, 1749
 Peckham JC, 533, 1471
 Pedersen-Bjergaard J, 1053
 Pelouze G, 551
 Penco S, 375
 Perez CA, 1867
 Perlia C, 1093
 Peterson AV, Jr, 1671
 Piana E, 499
 Pico JL, 805
 Pinals R, 1721
 Pinkham R, 1671
 Pinsky CM, 1663, 1693
 Piro AJ, 1275
 Pischer TL, 2071
 Piver MS, 559
 Pizzo PA, 247, 2031
 Plowman J, 31
 Poplack DG, 247, 2031
 Postescu ID, 823
 Pouillart P, 1613
 Powles TJ, 1427
 Pratesi G, 105, 375
 Pratt CB, 251, 1381, 1403, 2105
 Preisler HD, 505, 1393
 Presant CA, 461, 549
 Presnov MA, 705
 Priestman TJ, 2111
 Pritchard DJ, 205, 289
 Proctor JW, 1873
 Przybylski M, 1837

Q

Quagliana JM, 801
 Quinn FR, 45

R

Ragab A, 2109
 Ramirez G, 389
 Ramseur WL, 1085
 Ramu A, 1465
 Ransom JL, 1381
 Rao Y, 327
 Ratkin G, 461, 549
 Ratner LH, 1021
 Regelson W, 1853
 Repta AJ, 1359
 Rhyne L, 1085
 Ribaud P, 805
 Rice LS, 369, 1153
 Richards F II, 1085, 1233
 Richards RD, 1591
 Richardson RL, 1407
 Richman S, 1059
 Ringsborg U, 1413
 Ringsdorf H, 1837
 Ritchie JL, 941, 945
 Ritts RE, Jr, 289
 Rivera G, 251, 2105
 Roberts BJ, 1077, 1471
 Robinson J, 551
 Rodriguez V, 425, 493
 Roesdahl K, 449
 Roettger M, 1503
 Romanova LF, 705
 Rose WC, 779, 1337, 2085
 Rosen G, 345
 Rosenbloom B, 1295
 Rosenfeld JM, 23
 Rosowsky A, 1549
 Rossio JL, 1731
 Rossio AH, 1595
 Rothberg H, 569
 Roy R, 551
 Rozencweig M, 233
 Rubenstein L, 327
 Rubin J, 151, 837, 843, 1207, 1237, 1577
 Rucker N, 135

S

Sagebiel RW, 1703
 Saijo N, 139
 Sakamoto S, 453, 2063
 Salaman PF, 2111
 Salem P, 405, 1553
 Sallan SE, 829
 Salmon S, 455
 Samal B, 19
 Sampson D, 1623
 Samson MK, 163, 1223, 1599
 Santen RJ, 1581

Santicky MJ, 397
 Sarna GP, 681
 Savlov ED, 1093
 Schabel FM, Jr, 779, 1077, 1337, 1471, 2085
 Schein PS, 169, 563, 1145
 Schiffer LM, 727
 Schimpff SC, 673
 Schleupner CJ, 1931
 Schlumberger JF, 1971
 Schoenemann PT, 1025
 Schorer AE, 574
 Schulman SF, 1407
 Schultz RM, 1817, 1837, 1845, 1889, 1937, 1943
 Schulz J, 1613
 Schutt AJ, 483
 Schwarzenberg L, 805, 1613
 Seager ML, 2071
 Sedwick D, 341
 Sell KW, 1739
 Seltzer SE, 1271
 Senn HJ, 473
 Senzer NN, 1403
 Shackney SE, 479
 Shani A, 1237
 Shanks E, 251
 Shannon WM, 369, 1153, 1321
 Shapiro CM, 327
 Sheehan WW, 465
 Sheehy P, 1295
 Shellito J, 1397
 Shen DD, 13
 Shepp M, 295
 Sherif M, 993
 Shils M, 1041
 Shingleton HM, 833
 Siegel SE, 135
 Sieger L, 1295
 Sikic BI, 2011
 Silber R, 1367
 Silverman MA, 1587
 Sim FH, 205
 Simon LN, 1963
 Simon RM, 193, 846, 997, 1037, 1281
 Simpson-Herren L, 519
 Sims JE, 91
 Singer DH, 963
 Singer JW, 945
 Sinkovics JG, 1565
 Sinks LF, 239
 Sironi M, 111, 1975
 Sirotak FM, 1047
 Skeen MJ, 1651
 Skinner DG, 1709
 Skovsgaard T, 1053
 Slayton RE, 1211
 Sloss LJ, 923
 Smith AH, 1739
 Smith EH, 699
 Smith FP, 169
 Smith IE, 1427
 Smith LF, Jr, 563

Smith RB, 1709
 Snodgrass MJ, 1823
 Soble AR, 570
 Sofina ZP, 705
 Sonneveld P, 1033
 Sonntag RW, 473, 2125
 Sonoo H, 743
 Sordillo PF, 1573
 Sorensen SG, 941
 Soukop M, 489
 Spigel SC, 129
 Spitler LE, 1703
 Spitzer G, 1763
 Spreafico F, 111, 1975
 Spurr CL, 1085, 1233
 Staab R, 1603
 Stahly GP, 1585
 Staubus AE, 401
 Stephens RL, 129
 Sternberg SS, 693
 Sternson LA, 409, 1359
 Stetsenko AI, 705
 Stewart CC, 1867
 Stiteler RD, 1873
 Stock CC, 1575
 Stolfi RL, 1791
 Stoop JW, 1779
 Stoychkov JN, 2121
 Stratford IJ, 1406
 Strawitz JG, 389
 Strong EW, 1663
 Struck RF, 1321
 Stuart JJ, 1085, 1233
 Stylos WA, 1831, 1889, 1949
 Sugarbaker EV, 1587
 Suling WJ, 369, 1153, 1321
 Sulis E, 1408
 Surya YA, 23
 Sutow WW, 265
 Suzuki A, 139
 Symoens J, 1721

T

Tabbarah H, 1295
 Takenaka K, 743
 Takihara T, 743
 Takita H, 505
 Talley RW, 881, 1223
 Tannock I, 1117
 Tarnowski GS, 1575
 Tashima CK, 405, 1005, 1685
 Taylor DM, 721
 Taylor SG IV, 1203
 Taylor WF, 289
 Tejada F, 297
 Temkin NR, 1093
 Terrell W, 1403
 Thigpen T, 469, 801, 1101, 1215

Thompson EB, 1281
 Thompson M, 1509
 Thomsen J, 449
 Thorud E, 351
 Thurman GB, 1731, 1739
 Tillery KF, 75
 Timlin DM, 1769
 Tong WP, 529
 Townsend J, 177
 Trader MW, 779, 1337, 2085
 Traggis D, 259
 Trapani A, 963
 Trissel LA, 99
 Trivers G, 1731
 Troner MB, 2113
 Trujillo JM, 1513
 Trulock PD, 1569
 Tryka F, 1271
 Tschopp L, 2125
 Tsutsui M, 511
 Tura S, 1193
 Twentyman PR, 439

U

Uren J, 1549
 Uyama S, 743

V

Vaitkevicius VK, 553, 689, 1599
 Valdivieso M, 493, 1059, 1081, 1089, 1139, 1449, 1497, 1603
 Valeriote FA, 547, 737, 1313, 1867
 Van Echo DA, 1363
 van Eys J, 167
 van Lier JE, 1251
 Van Scoy-Mosher MB, 850
 Vaughn C, 455
 Vawter G, 217
 Vecchi A, 111, 1975
 Venditti JM, 576
 Veys E, 1721
 Vick NA, 1397
 Vietti TJ, 265, 547, 1313, 2109
 Vogel CL, 173, 1587, 2113
 Vogelzang NJ, 1595
 Vogler WR, 1569
 Volkers C, 1769
 Von Hoff DD, 233, 1421
 Vossen JM, 1779

W

Walker MD, 1199
 Wallace HJ, Jr, 1435

Wallach RC, 555, 1021
 Wampler GL, 333, 1093, 1355
 Wanebo HJ, 1663, 1693
 Wara DW, 1775
 Wara WM, 1775
 Warren R, 1281
 Watson E, 381
 Watts H, 217, 259
 Weaver SK, 881
 Weinerman B, 131
 Weinkam RJ, 1305
 Weiss AJ, 389
 Weiss JF, 1831
 Weiss RB, 847, 1405
 West WH, 1893
 Wharton JT, 1553
 Wheeler GP, 755
 Wheldon TE, 845
 White DR, 1085, 1233
 Whitecar J, 455, 469
 Wiernik PH, 1199, 1229, 1363, 1591
 Wijermans P, 1779
 Wilbanks GD, 1435
 Wilbur JR, 283
 Willans DJ, 571
 Williams D, 1857
 Williams SD, 1351
 Williams VR, 333
 Willson JKV, 2003
 Wilson CB, 177, 2071
 Winters R, 1873
 Wisnicki JL, 529
 Withers RH, 1081
 Wittes RE, 451
 Wodinsky I, 1025
 Wojtaszak B, 689
 Wolter J, 1211, 1595
 Wong DM, 1739
 Wong PP, 1333
 Wood D, 907
 Woolley CW, 1321
 Woolley PV, 563, 1145
 Wright PW, 1671

Y

Yagoda A, 463
 Yamagata J, 743
 Yamamura Y, 1873
 Yap H-Y, 405, 1005, 1685
 Yesair DW, 1025
 Youness E, 1513
 Young CW, 451, 1333
 Young D, 401
 Young JR, 570
 Young RC, 321, 429, 1375, 1421
 Youngner JS, 1881, 1915, 1931, 1937, 1943

Z

Zaharia M, 297
Zaharko DS, 1837

Zaren HA, 1139
Ziegler JL, 247, 1075, 1109, 2031
Zimble S, 295
Zimmermann A, 2125



